Abstract Funding Sources* AGA Oral and Poster Presentations at DDW ® 2017 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814 301.654.2055 (National Office) 301.654.3978 (Fax) www.gastro.org * Information contained in this report is current as of March 9, 2017.
73
Embed
Abstract Funding Sources* AGA Oral and Poster ......Abstract Funding Sources* AGA Oral and Poster Presentations at DDW ® 2017 AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Abstract Funding Sources*
AGA Oral and Poster Presentations at DDW® 2017
AGA Institute 4930 Del Ray Avenue Bethesda, MD 20814 301.654.2055 (National Office) 301.654.3978 (Fax) www.gastro.org
* Information contained in this report is current as of March 9, 2017.
GUIDETHERAPEUTIC DECISION-MAKING…(2*)| This study was financially supported in part by TBM grant T003716N of the Research Foundation – Flanders (FWO), Belgium. Sa2030. . . . . ANTI-TNF FOR POST-OPERATIVE PREVENTIONIN CROHN'S…(6*)|(2) Sa2031. . . . . SERUM ADALIMUMAB TROUGH LEVELSREQUIRED FOR…(2*)|(1) Sa2032. . . . . FINAL RESULTS ON EFFICACYAND SAFETY…(2*) Sa2033. . . . . THE INTRODUCTION OF INFLIXIMABTHERAPEUTIC DRUG…(5*) Sa2034. . . . . ASSESSMENT OF THE USEOF THERAPEUTIC…(5*) Sa2035. . . . . MONOCYTOSIS AS A BIOMARKERTO PREDICT…(5*) Sa2036. . . . . SERUM ADALIMUMAB LEVELS PREDICTSUCCESSFUL REMISSION…(2*) Sa2037. . . . . BIOMARKERS CALPROTECTIN AND C-REACTIVEPROTEIN CUT-OFF…(4*)|(5) Sa2038. . . . . INVESTIGATION OF THE INVITRO STABILITY…(3*)| IDKmonitor® Golimumab ELISA kits supplied free of charge by Biohit healthcare. Sa2039. . . . . IMPACT OF THE DURATIONOF COMBINATION…(1*) Sa2041. . . . . EFFICACY OF VEDOLIZUMAB ONEXTRAINTESTINAL MANIFESTATION…(5*) Sa2042. . . . . THERE IS NO DIFFERENCEIN SHORT-TERM…(5*) Sa2043. . . . . EFFECTIVENESS AND SAFETY OFCT-P13 UNDER…(3*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa2044. . . . . DISCONTINUATION OF CORTICOSTEROIDS AMONGULCERATIVE COLITIS…(3*)| The study was funded by Takeda Development Centre Europe Ltd. No medical writing assistance was provided. Sa2045. . . . . DISCONTINUATION OF CORTICOSTEROIDS AMONGCROHN'S DISEASE…(3*)| The study was funded by Takeda Development Centre Europe Ltd. Sa2046. . . . . USTEKINUMAB FOR THE TREATMENTOF CROHN…(5*) Sa2047. . . . . COMBINATION THERAPY OF VEDOLIZUMABAND A…(5*) Sa2048. . . . . EVALUATION OF TREATMENT PERSISTENCEOF VEDOLIZUMAB…(3*)| This study was funded by Takeda Oy. Sa2049. . . . . BIOSIMILAR INFLIXIMAB IN ANTI-TNFNAIVE IBD…(5*) Sa2050. . . . . INTENSIFIED INFLIXIMAB RESCUE THERAPYFOR ACUTE…(5*) Sa2051. . . . . EXCLUSIVE ENTERAL NUTRITION INADULTS WITH…(5*) Sa2052. . . . . NO INCREASE IN IMMUNOMODULATORUSE IN…(5*) Sa2053. . . . . INFLIXIMAB RE-INTRODUCTION AFTER TEMPORARYDISCONTINUATION: A…(5*) Sa2054. . . . . ULCERATIVE.COLITIS PATIENTS ON VEDOLIZUMABLACKING RESPONSE…(5*) Sa2055. . . . . COMBINATION THERAPY WITH ADALIMUMABAND IMMUNOMODULATORS…(5*) Sa2056. . . . . EFFICACY AND TOLERABILITY OFTHE AUTOIMMUNE…(4*) Sa2057. . . . . EFFICACY AND SAFETY OFSWITCHING FROM…(5*)
Sa2074. . . . . SHORT-TERM OUTCOMES OF ADALIMUMABFOR PATIENTS…(5*) Sa2075. . . . . LOW-DOSE AZATHIOPRINE IMPROVES LONG-TERMEFFICACY OF…(5*) Sa2076. . . . . COLECTOMY RATE TWO YEARSAFTER SEQUENTIAL…(5*) Sa2077. . . . . MAINTENANCE THERAPY WITH LOWERDOSE 5-AMINOSALICYLATE…(5*) Sa2078. . . . . COULD THE HYPERBARIC OXYGENTHERAPY BE…(5*) Sa2079. . . . . RAPID IMPROVEMENT IN SYMPTOMSAND QUALITY…(4*) Sa2080. . . . . ARE ANTI-TUMOR NECROSIS FACTORSASSOCIATED WITH…(5*) Sa2081. . . . . USTEKINUMAB IS EFFECTIVE FORINDUCING CLINICAL,…(7*)| The Canadian Association of Gastroenterology Sa2082. . . . . DOES STATIN USE REDUCETHE RISK…(5*) Sa2083. . . . . ANTI-TNF THERAPY IN REFRACTORYPOUCHITIS AND…(5*) Sa2084. . . . . INTESTINAL ORGANOIDS DERIVED FROMINFLAMED TISSUES…(4*)|(2) Sa2085. . . . .REDUCED MITOCHONDRIAL FUNCTION IN THE INFLAMED…(2*)|(4) Sa2086. . . . . LACK OF INTESTINAL VDRREGULATION LEADS…(2*) Sa2087. . . . . RESVERATROL COUNTERACTS TNF-ALPHA-INDUCED INHIBITIONOF INTESTINAL…(2*) Sa2088. . . . . ENDOSCOPICALLY ASSISTED GLUCOSE BREATHTEST (EAGBT):…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa2089. . . . . COLIFORM AND UPPER RESPIRATORYTRACT BACTERIAL…(5*) Sa2090. . . . . TH-RELATED CYTOKINES PROMOTE FIBROSISTHROUGH HUMAN…(5*) Sa2091. . . . . COUNTERACTION OF ISCHEMIC COLITISLESION IN…(2*) Sa2092. . . . . MECHANISMS UNDERLYING THE NON-ANTICOAGULANTEFFECTS OF…(5*) Sa2093. . . . . ENTERIC PROTECTIVE EFFECTS OFTHE COMBINATION…(5*) Sa2094. . . . . IT DOESN'T TAKE ALOT OF…(5*) Sa2095. . . . . ARGON PLASMA COAGULATION ALONEOR IN…(5*) Sa2096. . . . . ELEVATED NO PRODUCTION ISPROTECTIVE AGAINST…(4*) Sa2097. . . . . ENDOSCOPIC FINDINGS ARE SIGNIFICANTFACTOR ASSOCIATED…(5*) Su1000. . . . . AFRICAN AMERICAN PATIENTS ARELESS LIKELY…(5*) Su1001. . . . . INSURANCE STATUS IMPACTS TREATMENTFOR HEPATOCELLULAR…(5*) Su1002. . . . . DISPARITIES IN THE TREATMENTOF HEPATOCELLULAR…(5*) Su1003. . . . . COLORECTAL CANCER AT ANURBAN VETERANS'…(5*) Su1004. . . . . EFFECT OF RACE ANDGENDER ON…(5*) Su1005. . . . . LOCATION OF HEALTHCARE DELIVERY(COUNTY VS…(5*) Su1006. . . . . PATHOLOGY AND DISTRIBUTION OFCOLONIC POLYPS…(5*)
Su1007. . . . . A COMPARISON OF HOSPITALIZATIONSOF AFRICAN-AMERICAN…(5*) Su1008. . . . . DISPARITIES IN CLINICAL OUTCOMESIN AFRICAN…(5*) Su1009. . . . . THE ASSOCIATION BETWEEN RACEAND THE…(5*) Su1010. . . . . CLINICAL FACTORS ASSOCIATED WITHHIGH-RISK PATIENTS…(5*) Su1011. . . . . TRENDS IN STATIN PRESCRIPTIONSAMONG PATIENTS…(5*) Su1012. . . . . UNINSURED PATIENTS WITH CIRRHOSISAND ASCITES…(5*) Su1013. . . . . IDENTIFYING GENDER BARRIERS FORENDOSCOPY ACCESS:…(5*) Su1014. . . . . RESOURCE UTILIZATION AND COLORECTALCANCER SCREENING…(6*) Su1015. . . . . LOW INCOME, AFRICAN AMERICANRACE AND…(5*) Su1016. . . . . FREQUENCY OF GASTROINTESTINAL SYMPTOMSOF DENGUE…(5*) Su1017. . . . . INCREASING ECONOMIC BURDEN OFINPATIENT IBD…(5*) Su1018. . . . . FACTORS THAT DELAY DISCHARGEAFTER ADMISSION…(1*) Su1019. . . . . ACUTE PANCREATITIS REGIONAL ANDDIVISIONAL COST…(4*) Su1021. . . . . A SUCCESSFUL PHARMACIST BASEDQUALITY INITIATIVE…(5*) Su1022. . . . . THE TRUE COST OFULCERATIVE COLITIS…(3*)| Allergan funded the release the acquisition of HES data
Su1023. . . . . IN-PATIENT HEALTHCARE UTILIZATION ASSOCIATEDWITH OBESITY:…(4*) Su1024. . . . . COST-EFFECTIVENESS OF MELANOMA SCREENINGIN INFLAMMATORY…(5*) Su1025. . . . . COST-EFFECTIVENESS OF INFLIXIMAB'S BIOSIMILARCT-P13 COMPARED…(2*)|(4) Su1026. . . . . 30-DAY UNPLANNED READMISSION RATES,COST AND…(5*) Su1027. . . . . DIRECT HEALTHCARE COSTS ASSOCIATEDWITH OSTEOPOROSIS…(3*)| Gilead Sciences, Inc. Su1028. . . . . THE TOTAL DIRECT COSTOF HEALTHCARE…(3*)| |Celgene) Su1029. . . . . COST-EFFECTIVENESS ANALYSIS OF HELICOBACTERPYLORI DIAGNOSTIC…(4*) Su1032. . . . . INTEROBSERVER AGREEMENT AFTER ADDITIONOF P53…(5*) Su1033. . . . . ADHERENCE TO QUALITY INDICATORSFOR THE…(5*) Su1034. . . . . RISK OF PROGRESSION AFTERA DIAGNOSIS…(2*)|(4) Su1035. . . . . META-ANALYSIS OF MISSED HIGHGRADE DYSPLASIA…(2*) Su1036. . . . . THE IMPACT OF BARRETT'SESOPHAGUS ON…(5*) Su1037. . . . . THE IMPACT OF SURVEILLANCEENDOSCOPY ON…(5*) Su1038. . . . . PREVALENCE AND PREDICTORS OFMISSED DYSPLASIA…(5*) Su1039. . . . . IMPACT OF SURVEILLANCE INBARRETT'S ESOPHAGUS…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1040. . . . . CANNABINOID RECEPTOR 1 ANDEPIDERMAL GROWTH…(5*) Su1041. . . . . YOUNGER AGE OF ONSETOF BARRETT'S…(5*) Su1042. . . . . ADHERENCE TO BARRETT'S ESOPHAGUSSURVEILLANCE GUIDELINES:…(5*) Su1043. . . . . EXTERNAL VALIDATION OF THEMICHIGAN BARRETT'S…(5*) Su1044. . . . . PROPORTION OF GASTROESOPHAGEAL REFLUXDISEASE AND…(5*) Su1045. . . . . TEN YEARS OF RADIOFREQUENCYABLATION (RFA)…(5*) Su1046. . . . . CASE-CONTROL STUDY OF THEPREVALENCE OF…(5*) Su1047. . . . . LOW RISK OF SUSPECTEDLONG SEGMENT…(4*) Su1048. . . . . BARRETT'S ESOPHAGUS SCREENING ANDSURVEILLANCE IS…(5*) Su1049. . . . . MUTATION STATUS OF BARRETT'SESOPHAGUS BIOPSIES…(4*) Su1050. . . . . RISK FACTORS FOR PROGRESSIONOF BARRETT'S…(5*) Su1051. . . . . USE OF MOLECULAR ANALYSISTO INFORM…(4*) Su1052. . . . . GENOMIC TESTING OF ENDOSCOPICBIOPSIES AID…(2*) Su1053. . . . . NEOPLASTIC PROGRESSION IN PATIENTSWITH SHORT…(5*) Su1054. . . . . INFLUENCE OF PERSISTENT LGDON PROGRESSION…(5*) Su1055. . . . . ACCEPTABILITY OF TISSUE COLLECTIONBY CYTOSPONGE…(2*)|(4)|Covidien LP/Medtronic
Su1056. . . . . SLEEVE GASTRECTOMY IS ARISK FACTOR…(5*) Su1057. . . . . VOLUMETRIC LASER ENDOMICROSCOPY FINDINGSCAN RISK…(3*)| NinePoint Medical, Inc. Su1058. . . . . DISTAL ESOPHAGEAL IMPEDANCE MEASUREMENTSDURING HIGH…(5*) Su1059. . . . . HISTOLOGIC PROGRESSION DURING TREATMENTWITH RADIOFREQUENCY…(2*)|(4) Su1060. . . . . ACID INHIBITION ATTAINED BYCONCOMITANT ADMINISTRATION…(4*)|(2)||The First Department of Medicine and the Center for Clinical Research at Hamamatsu University School of Medicine have received grants from Takeda Pharmaceutical Co., Ltd., AstraZeneca KK, Eisai Co., Ltd. and Daiichi-Sankyo Co. Ltd. Su1061. . . . . THE EFFICACY AND SAFETYOF RABEPRAZOLE…(3*) Su1062. . . . . PREDICTORS OF NON-RESPONSE TOACID SUPPRESSION…(5*) Su1063. . . . . EFFECT OF CJ-12420, ANOVEL POTASSIUM-COMPETITIVE…(3*) Su1064. . . . . TOPICAL PROTECTION OF HUMANOESOPHAGEAL MUCOSAL…(2*) Su1065. . . . . EFFECTIVENESS OF MANAGEMENT ONHEALTH-RELATED AND…(5*) Su1066. . . . . EFFECTIVENESS OF ON-DEMAND THERAPYUSING 20-MG…(5*) Su1067. . . . . A SLEEP POSITIONING DEVICEFOR REFRACTORY…(2*) Su1068. . . . . PREDICTORS OF PERSISTENT GASTROESOPHAGEALREFLUX SYMPTOMS…(5*) Su1069. . . . . FACTORS ASSOCIATED WITH NEEDFOR RE-DO…(5*)
Su1070. . . . . PRE-OPERATIVE ESOPHAGEAL MOTILITY DISORDERSARE NOT…(5*) Su1071. . . . . EFFICACY OF A POTASSIUM-COMPETITIVEACID BLOCKER…(5*) Su1072. . . . . PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITYOF DWP14012,…(3*)| Daewoong Pharmaceutical Co., Ltd., Korea Su1073. . . . . OMEGA-CUFF: A NOVEL IMPLANTTO AUGMENT…(2*) Su1074. . . . . AN ASSESSMENT OF THERELATIONSHIP BETWEEN…(3*)| The studies were funded by AstraZeneca, which entered into an agreement with Pfizer for the over-the-counter (OTC) rights for NEXIUM® (esomeprazole magnesium). Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC. Su1075. . . . . LAPAROSCOPIC NISSEN AGAINST ANTERIORPARTIAL FUNDOPLICATION…(5*) Su1076. . . . . EFFECT OF COGNITIVE BEHAVIOURALTHERAPY ON…(4*)|(3)|Sandhill Sci, (Denver, USA) Su1077. . . . . TREATMENT OF MILD GASTROESOPHAGEALREFLUX DISEASE…(5*) Su1078. . . . . A PILOT, PHASE IV,RANDOMIZED, DOUBLE-BLIND,…(3*)| Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, and was funded by Pfizer Inc.) Su1079. . . . . AN ANALYSIS OF THEPERCENTAGE OF…(3*)| The studies were funded by AstraZeneca, which entered into an agreement with Pfizer for the over-the-counter (OTC) rights for NEXIUM® (esomeprazole magnesium). Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, Su1080. . . . . VISIBLE LESIONS IN BARRETT'SESOPHAGUS: CLINICAL…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1081. . . . . THE OPTIMAL TIMING TOMODIFY THE…(7*) Su1082. . . . . THE INFLUENCE OF DEPRESSIONAND ANXIETY…(7*) Su1083. . . . . DEVELOPMENT AND VALIDATION OFA SIMPLE…(7*) Su1084. . . . . GASTRIN ELEVATION FOLLOWING PROTONPUMP INHIBITOR…(5*) Su1085. . . . . WIRELESS ELECTRICAL STIMULATION FORMANAGING GASTROESOPHAGEAL…(5*) Su1086. . . . . A SYSTEMATIC REVIEW ANDNETWORK META-ANALYSIS…(3*)| Takeda Pharmaceutical Company Limited Su1087. . . . . A SYSTEMATIC REVIEW ANDNETWORK META-ANALYSIS…(3*)| |Takeda Pharmaceutical Company Limited Su1088. . . . . TO COMPARE THE EFFICACYAND SAFETY…(5*) Su1089. . . . . GERD PREVALENCE AND TREATMENTIN PRIMARY…(5*) Su1090. . . . . PRELIMINARY RESULTS OF APROSPECTIVE MULTICENTER…(3*)| EndoStim BV Su1091. . . . . ELECTRICAL STIMULATION THERAPY (EST)OF THE…(3*)| EndoStim BV Su1108. . . . . SPORADIC FUNDIC GLAND POLYPSAND LEVEL…(5*) Su1109. . . . . EFFICACY OF PPI +ASA REGIMEN…(5*) Su1110. . . . . INDIVIDUAL ASSESSMENT OF GASTRICACID PRODUCTION…(5*) Su1111. . . . . RECOVERY OF GASTRIC FUNCTIONIN CHRONIC…(5*)
Su1112. . . . . AGGRESSIVE AND ADVANCED NON-CARDIAGASTRIC CANCER…(5*) Su1113. . . . . THE CURRENT TRENDS OFGASTRIC POLYPS…(5*) Su1114. . . . . FOLLOW-UP RESULT OF SUBEPITHELIALLESIONS DIAGNOSED…(5*) Su1115. . . . . THE STAGING OF GASTRITISWITH THE…(5*) Su1116. . . . . GASTRIC INTESTINAL METAPLASIA TYPEIII AND…(2*) Su1117. . . . . AUTOPHAGIC PROTEINS AS MARKERSOF DYSPLASTIC…(5*) Su1118. . . . . VALIDATION OF SERUM MARKERSIN MONGOLIA…(2*) Su1119. . . . . WHERE IS THE BLEEDINGSITE IN…(4*)|(2) Su1120. . . . . IS HEMOSTASIS WITH DOPPLERENDOSCOPIC PROBE…(4*)|(2) Su1121. . . . . SMALL BOWEL AND OTHERGI LESIONS…(4*) Su1122. . . . . UPPER GASTROINTESTINAL MUCOSAL INJURYAND SYMPTOMS…(5*) Su1123. . . . . TURNING OFF THE DRIP:A SINGLE…(5*) Su1124. . . . . PREVALENCE AND RISK FACTORSFOR GASTROINTESTINAL…(4*) Su1125. . . . . INFECTION IS ASSOCIATED WITHGASTROINTESTINAL BLEEDING…(5*) Su1126. . . . . SOMATOSTATIN ANALOGUES ARE HIGHLYEFFECTIVE IN…(5*) Su1127. . . . . A MULTICENTRE OBSERVATIONAL STUDYON STRESS…(3*)| |This study was funded by AstraZeneca.)
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1144. . . . . PATTERN OF THYROID DISEASEPRESENTATION IN…(4*) Su1145. . . . . CONCERNS REGARDING GLUTEN PRESENCEIN MEDICINES…(2*)|The US Food and Drug Administration awarded Beyond Celiac a grant to conduct a research study in gluten in medicine (#4288). Su1146. . . . . A POPULATION-BASED ANALYSIS OFTHE CONTRIBUTION…(5*) Su1147. . . . . ETHNIC AND GENDER VARIATIONOF ANTI-TISSUE…(5*) Su1240. . . . . A NATIONWIDE TREND ANALYSISOF PATIENTS…(4*) Su1241. . . . . IN-HOSPITAL MORTALITY AND ANDRESOURCE UTILIZATION…(4*) Su1242. . . . . THE IMPACT OF PORTALVEIN THROMBOSIS…(4*) Su1243. . . . . PERITONEAL CAVITY DIAMETER ISASSOCIATED WITH…(4*) Su1244. . . . . FREQUENCY AND PROGNOSIS OFACUTE PANCREATITIS…(5*) Su1245. . . . . ACUTE PANCREATITIS (AP) ANDTHE WEEKEND…(1*) Su1246. . . . . THE CHANGING UTILIZATION OFIMAGING MODALITIES…(5*) Su1247. . . . . ASSOCIATION OF DIETARY HABITSWITH SEVERE…(5*) Su1248. . . . . THE SYSTEMIC INFLAMMATORY RESPONSESYNDROME (SIRS)…(5*) Su1249. . . . . IMPACT OF EARLY FLUIDTHERAPY ON…(5*) Su1250. . . . . INCIDENCE, ETIOLOGY, AND OUTCOMEOF ACUTE…(5*) Su1251. . . . . THE IMPACT OF METFORMININ OVERALL…(5*)
Su1252. . . . . SUITABLE LIQUID BIOPSY SAMPLESFOR DETECTING…(5*) Su1253. . . . . HISTOLOGY CORE OBTAINED WITHA NOVEL…(5*) Su1254. . . . . ALTERED EXPRESSION OF TIGHTJUNCTION (TJ)…(2*) Su1255. . . . . PARANEOPLASTIC WEIGHT LOSS ANDRISE IN…(4*)|(5) Su1256. . . . . A MULTICENTER, OPEN-LABEL, RANDOMIZEDCONTROLLED TRIAL…(4*)|(5) Su1257. . . . . SUBOPTIMAL INTEROBSERVER AGREEMENT (IOA)AMONGT CYTOPATHOLOGISTS…(4*)| Supported by the Department of Medicine Outstanding Early Scholars Program Su1258. . . . . QUANTITATIVE DETECTION OF SPARCGENE PROMOTER…(2*) Su1259. . . . . THE EFFICACY AND SAFETYOF PANCREATIC…(1*) Su1260. . . . . FATTY PANCREAS IS ASSOCIATEDWITH PANCREATIC…(5*) Su1261. . . . . IMPLEMENTING A MULTIDISCIPLINARY CONFERENCEIMPROVES PATIENT…(5*) Su1262. . . . . SERUM LEVELS OF INSULIN-LIKEGROWTH FACTOR…(5*) Su1263. . . . . AUTOPHAGY FAILS TO SUSTAINPROLIFERATION OF…(2*) Su1264. . . . . CHARACTERIZATION OF MIRNAS INCHRONIC PANCREATITIS…(2*) Su1265. . . . . CURATIVE INTENT SURGERY INBORDERLINE RESECTABLE…(5*) Su1266. . . . . FASTING HUMAN PANCREATIC POLYPEPTIDE(HPP) LEVEL…(4*)
Su1267. . . . . THE BURDEN OF PANCREATICCANCER IN…(2*) Su1268. . . . . THE INFLUENCE OF PROTONPUMP INHIBITORS…(2*)| The work was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000003. Su1269. . . . . PREOPERATIVE SARCOPENIA AND ACCELERATEDMUSCLE LOSS…(5*) Su1270. . . . . PROGNOSTIC ROLE OF HEDGEHOGSIGNALING PATHWAY…(4*)|(2) Su1271. . . . . PARANEOPLASTIC DIFFERENTIAL ADIPOSE TISSUELOSS IMPACTS…(5*) Su1272. . . . . National Pancreas Foundation’s (NPF)Patient Education…(5*) Su1273. . . . . ENDOSCOPIC ULTRASOUND FINDING INPATIENTS WITH…(1*) Su1274. . . . . HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)THERAPY FOR…(5*) Su1276. . . . . THE USE OF PHOTODYNAMICTHERAPY IN…(4*)| Pinnacle Biologics Su1277. . . . . ENDOSCOPIC ULTRASOUND AS APREDICTOR AND…(5*) Su1278. . . . . PREDICTORS OF SHORT-TERM ANDLONG-TERM RESOLUTION…(5*) Su1390. . . . . CHOLANGIOPATHIC PATTERNS DETECTED BYMAGNETIC RESONANCE…(2*) Su1391. . . . . RESET CUT-OFF VALUE OFELEVATED ALKALINE…(5*) Su1392. . . . . EVALUATION OF A PROPOSEDSCORING SYSTEM…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1393. . . . . EFFICACY OF ENDOSCOPIC BILIARYSTENTS IN…(5*) Su1394. . . . . PREVALENCE OF PRE-OPERATIVE HYPERBILIRUBINEMIAAND PREDICTORS…(5*) Su1395. . . . . RISK FACTORS FOR REFRACTORYBACTERIA IN…(5*) Su1396. . . . . THE ASSOCIATION OF GALLSTONEAND CHOLECYSTECTOMY…(5*) Su1397. . . . . A STUDY TO INVESTIGATERISK FACTOR…(5*) Su1398. . . . . PREDICTORS OF BILE TREEPATHOLOGY IN…(5*) Su1399. . . . . EFFICACY AND SAFETY OFNON-FLUOROSCOPIC ENDOSCOPIC…(5*) Su1400. . . . . RELAPSING FACTORS AFTER PERCUTANEOUSCHOLECYSTOSTOMY FOR…(5*) Su1401. . . . . IS ANTIMICROBIAL RESISTANCE TOINITIAL ANTIBIOTIC…(5*) Su1402. . . . . ELEVATED CONCENTRATION OF BILEACIDS AND…(5*) Su1403. . . . . ASYMPTOMATIC COMMON BILE DUCTDILATION AND…(5*) Su1404. . . . . COMPARISON BETWEEN DIRECT DIGITALCHOLANGIOSCOPY AND…(5*) Su1406. . . . . CLINICAL CHARACTERISTICS OF CLONORCHISSINENSIS ASSOCIATED…(1*) Su1407. . . . . ERCP GUIDED BILE ASPIRATECULTURE CAN…(5*) Su1408. . . . . CAUSATIVE PATHOGENS PATTERN ANDCLINICAL OUTCOMES…(5*)
Su1409. . . . . TIMING OF ERCP ANDINPATIENT MORTALITY…(5*) Su1508. . . . . 13C MANNITOL IS SUPERIORTO 12C…(2*)|(4) Su1509. . . . . INVOLVEMENT OF GLIADIN, ACOMPONENT OF…(5*) Su1510. . . . . COLONIC LOAD DIFFERENTIATES ORGANIZATIONOF MUCUS…(2*) Su1511. . . . . LEPTIN ALLEVIATES INTESTINAL MUCOSALBARRIER INJURY…(5*) Su1512. . . . . PPI AGGRAVATED LEAKY GUTSYNDROME, WHILE…(5*) Su1513. . . . . GLP-2 ACUTELY AMELIORATES LPS-RELATEDINTESTINAL PERMEABILITY…(2*)|Shire Pharmaceuticals) Su1514. . . . . ZONULIN TRANSGENIC MOUSE MODELSHOWS ALTERED…(4*) Su1515. . . . . PLECANATIDE AND DOLCANATIDE, GUANYLATECYCLASE-C AGONISTS,…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1516. . . . . HYDROXY-Α-SANSHOOL INDUCED NNOS-MEDIATED LONGDISTANCE CONTRACTION…(3*)| Tsumura & Co. Su1517. . . . . EFFICACY AND SAFETY OFPLECANATIDE IN…(3*)| Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1518. . . . . PLECANATIDE FOR THE TREATMENTOF CHRONIC…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo
used for the study. Writing and editorial support provided by The Medicine Group. Su1519. . . . . CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCEREGULATOR CHANNEL…(5*) Su1520. . . . . PREVALENCE OF JOINT HYPERMOBILITYVARIES BETWEEN…(5*) Su1521. . . . . SYMPTOM AND ANORECTAL MANOMETRYCHARACTERISTICS OF…(1*) Su1522. . . . . EFFECTS OF NALDEMEDINE, A PERIPHERALLY ACTING…(3*)| Shionogi & Co., Ltd Su1523. . . . . EXPERIENCE WITH AN EMERGINGCLINICAL TRIAD:…(2*) Su1524. . . . . OPTIMIZED TIBIAL NERVE STIMULATIONIMPROVES OPIATE-INDUCED…(5*) Su1525. . . . . USE OF METHYLNALTREXONE INCANCER PATIENTS…(5*) Su1526. . . . . THE RELATIONSHIP OF PATIENT-REPORTEDTREATMENT SATISFACTION…(3*)| Allergan, plc, and Ironwood Pharmaceuticals, Inc. Su1527. . . . . ASSOCIATION OF SLEEP DISORDERSAND RELATED…(5*) Su1528. . . . . RECTAL GAS VOLUME: AUSEFUL SCREENING…(5*) Su1529. . . . . THE DIAGNOSTIC VALUE OFBALLOON EXPLUSION…(5*) Su1530. . . . . FECAL BURDEN ON ABDOMINALCOMPUTERIZED TOMOGRAPHY…(5*) Su1531. . . . . THE UROGUANYLIN ANALOG PLECANATIDEACTIVATES GUANYLATE…(3*)|Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1532. . . . . INDIRECT TREATMENT COMPARISON: PLACEBO-ADJUSTEDRESULTS FROM…(3*)| Allergan, plc, and Ironwood Pharmaceuticals, Inc. Su1533. . . . . RESULTS FROM THE BURDEN–CICSTUDY (BETTER…(3*)| Funding for these trials and editorial support were provided by Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals Inc. also provided the plecanatide and placebo used for the study. Writing and editorial support provided by The Medicine Group. Su1534. . . . . SECRETORY DIARRHEA AND HYPOKALEMIAASSOCIATED WITH…(5*) Su1535. . . . . ADVANCED GLYCATION END PRODUCTSINDUCE COLONIC…(5*)| National Natural Science Foundation of China (No. 81470813) Su1536. . . . . AGREEMENT BETWEEN DYNAMIC TRANSRECTALULTRASOUND AND…(5*) Su1537. . . . . HERBAL LAXATIVE USE ISCOMMON AND…(7*) Su1538. . . . . PAINFUL CONSTIPATION: ABDOMINAL PAININ PATIENTS…(5*) Su1539. . . . . IMPACT OF AGE ANDGENDER TO…(1*) Su1540. . . . . PERIOPERATIVE INFLAMMATORY MARKER ASA PREDICTIVE…(5*) Su1541. . . . . GASTROINTESTINAL TRANSIT PATTERNS IDENTIFIEDIN CHILDREN…(2*) Su1542. . . . . LINACLOTIDE FOR THE TREATMENTOF PATIENTS…(5*) Su1543. . . . . DOSE-FINDING OF LINACLOTIDE FORPATIENTS WITH…(3*)| Supported by Astellas Pharma, Inc.
Su1544. . . . . ATTRIBUTABLE BENEFIT -- INTERPRETINGRESULTS FROM…(5*) Su1545. . . . . A NOVEL SYSTEM ANDMETHODOLOGY FOR…(2*) Su1546. . . . . CLINICAL UTILITY OF THEGASTRIC EMPTYING…(5*) Su1547. . . . . DEVELOPMENT AND PSYCHOMETRIC EVALUATIONOF THE…(3*)| This study was supported by Motus Therapeutics, Inc. Su1548. . . . . INTRAGASTRIC MEAL DISTRIBUTION (IMD)DURING ROUTINE…(2*) Su1549. . . . . SYMPTOMS ASSOCIATED WITH GASTROPARESISIN COMMUNITY-BASED…(5*) Su1550. . . . . DIFFERENCES BETWEEN OBESE ANDNON-OBESE PATIENTS…(2*) Su1551. . . . . HOSPITALIZATIONS AND READMISSIONS FORGASTROPARESIS: CHARACTERIZATION…(5*) Su1552. . . . . RELATIONSHIPS BETWEEN SLOW WAVEFREQUENCY, CONDUCTION…(2*) Su1553. . . . . HIGH INCIDENCE OF GASTRICBEZOARS AND…(5*) Su1554. . . . . RELATION OF OPIATE USETO CLINICAL…(2*) Su1555. . . . . SMARTPILL GASTRIC EMPTYING TIMESTRONGLY CORRELATES…(2*) Su1556. . . . . GASTRIC EMPTYING AND SYMPTOMSDURING A…(2*) Su1557. . . . . SIGNIFICANT ALTERATIONS WITHIN THEPLASMA CYTOKINE…(5*) Su1558. . . . . DELAYED GASTRIC EMPTYING ISASSOCIATED WITH…(5*)
Su1559. . . . . BASIS OF ELECTROGASTROGRAPHY (EGG)REVISITED USING…(2*) Su1560. . . . . SUBTYPES OF GASTROPARESIS (GP):CHARACTERISTICS OF…(5*) Su1561. . . . . CONCOMITANT USE OF PROKINETICMEDICATIONS AFTER…(5*) Su1562. . . . . THE SAFETY PROFILE OFWIRELESS MOTILITY…(5*) Su1563. . . . . LONG TERM EFFICACY OFGASTRIC ELECTRICAL…(5*) Su1564. . . . . GASTRIC ELECTRICAL STIMULATION ISASSOCIATED WITH…(2*) Su1565. . . . . ARE BREATH TESTS HELPFULIN PREDICTING…(1*) Su1566. . . . . SMALL INTESTINAL BACTERIAL OVERGROWTHACCELERATES TRANSIT…(6*) Su1567. . . . . ASSESSMENT OF SMALL BOWELMOTILITY IN…(4*) Su1568. . . . . TGFB SUPPRESSES ENTERIC NEUROGENESIS:A POTENTIAL…(2*) Su1569. . . . . INITIAL PARADOXICAL PEAKS ONBREATH TESTING…(3*)| This study was supported jointly by Commonwealth Laboratories, LLC, and Synthetic Biologics, Inc. Su1570. . . . . ELEVATED METHANE LEVELS INSMALL INTESTINAL…(5*) Su1571. . . . . EFFECT OF REPAGLINIDE ONTHE SMOOTH…(2*) Su1572. . . . . EFFECTS OF ANTIDIABETIC AGENTSON GASTROINTESTINAL…(4*) Su1573. . . . . PATIENTS ARE UNCOMFORTABLE WITHTHE USE…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1574. . . . . UNDERSTANDING WHY OLDER PATIENTSCONTINUE LOW-VALUE…(5*) Su1575. . . . . VALUE OF MAGNIFICATION ENDOSCOPYWITH ACETIC…(5*) Su1576. . . . . ASSOCIATION BETWEEN EDUCATION ANDCOLORECTAL CANCER…(5*) Su1577. . . . . PREDICTORS OF INADEQUATE BOWELPREPARATION IN…(5*) Su1578. . . . . A MULTILEVEL QUALITY IMPROVEMENTINITIATIVE TO…(5*) Su1579. . . . . PATIENTS AND PHYSICIANS AREAMENABLE TO…(5*) Su1580. . . . . COMPARING THE REAL WORLDEFFECTIVENESS OF…(4*) Su1581. . . . . SCREENING COLONOSCOPY IN ANORTHWESTERN POPULATION…(5*) Su1582. . . . . A NATIONAL SURVEY ONPHYSICIAN'S ACCEPTANCE…(4*) Su1583. . . . . THE USE OF APOPULATION SPECIALIST…(5*) Su1584. . . . . ENDOSCOPY IS OF LOWYIELD IN…(5*) Su1585. . . . . RISK FACTORS FOR THEDEVELOPMENT OF…(5*) Su1586. . . . . FRAILTY AND AGE MAYNOT ADEQUATELY…(5*) Su1587. . . . . STRAYING FROM SURVEILLANCE COLONOSCOPYGUIDELINES FOR…(5*) Su1588. . . . . SHOULD EVERYONE WITH ADVANCEDADENOMATOUS LESIONS…(5*) Su1589. . . . . CAN WE PREDICT THEDISCOVERY OF…(5*)
Su1590. . . . . DO WE PRACTICE WHATWE PREACH?…(5*) Su1591. . . . . HEPATITIS C SCREENING RATESIN BABY…(5*) Su1592. . . . . PREVALENCE OF SESSILE SERRATEDADENOMATOUS POLYPS…(5*) Su1593. . . . . TARGETED METABOLIC PROFILING OFTYROSINE IN…(5*) Su1594. . . . . COLORECTAL CANCER SCREENING WITHCOLOGUARD IN…(5*) Su1595. . . . . GILBERT SYNDROME IS NOTTHAT INNOCENT!…(4*) Su1596. . . . . EFFICACY OF CIMETROPIUM BROMIDEON POLYP…(5*) Su1597. . . . . ENVIRONMENTAL FACTORS FROM APROSPECTIVE STUDY…(2*) Su1720. . . . . POOLED INCIDENCE OF FECALOCCULT BLOOD…(5*) Su1721. . . . . DIFFERENCES IN COLONOSCOPY ASSOCIATEDCOSTS BETWEEN…(5*) Su1722. . . . . COST-EFFECTIVENESS OF PATIENT OUTREACHTO INCREASE…(2*) Su1723. . . . . COST-EFFECTIVENESS OF SURVEILLANCE GUIDELINESFOR PATIENTS…(2*) Su1724. . . . . INTERVAL CANCERS IN FIT-BASEDSCREENING PROGRAM…(5*) Su1725. . . . . REPEAT ANNUAL FECAL IMMUNOCHEMICALTESTING PATTERNS…(2*) Su1726. . . . . DOES THE LEVEL OFA NEGATIVE…(5*) Su1727. . . . . CRC SCREENING IN WOMENAGE 50-59…(2*)
Su1728. . . . . RISK OF COLORECTAL NEOPLASMSIN FIRST-DEGREE…(2*) Su1729. . . . . INTER-OBSERVER AGREEMENT AMONG PATHOLOGISTSIN THE…(5*) Su1730. . . . . TIME TO DIAGNOSTIC COLONOSCOPYAND COLONOSCOPIC…(5*) Su1731. . . . . PERFORMANCE OF MULTITARGET STOOLDNA TESTING…(2*)| Multitarget sDNA analyses provided by Exact Sciences, Inc. Su1732. . . . . RISK OF ADVANCED COLORECTALNEOPLASIA ACCORDING…(5*) Su1733. . . . . EVALUATION OF A GENEEXPRESSION PANEL…(2*)|(4) Su1734. . . . . ISOLATED SMALL RIGHT-SIDED HYPERPLASTICPOLYPS CONFER…(5*) Su1735. . . . . IMMUNOHISTOCHEMISTRY PROFILE OF BASELINESESSILE SERRATED…(2*)|(7)|American College of Gastroenterology Su1736. . . . . GENETIC PROFILE OF POLYPSAND RISK…(5*) Su1737. . . . . SYMPTOMATIC PATIENTS PARTICIPATING INCOLORECTAL CANCER…(5*) Su1738. . . . . ANNUAL FECAL IMMUNOCHEMICAL TESTINGIS AS…(2*) Su1739. . . . . ADENOMATOUS LESIONS AMONG ADULTSURVIVORS OF…(5*) Su1740. . . . . EVALUATION OF A MULTIMODALCOLORECTAL CANCER…(2*) Su1741. . . . . YOUNG-ONSET COLORECTAL CANCER INA MULTI-ETHNIC,…(6*)| Scripps Health Foundation Su1742. . . . . COLORECTAL CANCER RISK FACTORSIN VETERANS…(2*)|(4)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1743. . . . . CONSENSUS RECOMMENDATIONS FOR COLORECTALCANCER SCREENING…(6*) Su1744. . . . . IMPACT OF THE ORGANIZEDSCREENING PROGRAM…(4*) Su1745. . . . . AN ONLINE RISK ASSESSMENTTOOL DEMONSTRATES…(5*) Su1746. . . . . AN ONLINE RISK ASSESSMENTTOOL DEMONSTRATES…(5*) Su1747. . . . . FOLLOW-UP OF PATIENTS UNNDERGOINGCOLONOSCOPY ASSESSEMENT…(4*) Su1748. . . . . COST-EFFECTIVENESS ANALYSIS OF COLONOSCOPYCOLORECTAL CANCER…(6*)|(2) Su1749. . . . . COLORECTAL CANCER SCREENING INA FIT…(2*) Su1750. . . . . A NURSE-LED MODEL INCREASESCONCORDANCE WITH…(5*) Su1751. . . . . UPTAKE OF A COLORECTALCANCER SCREENING…(4*) Su1752. . . . . ANALYSIS OF THE CUT-OFFVALUE OF…(5*) Su1753. . . . . JAPANESE COLORECTAL CANCERS DATADEPENDING ON…(5*) Su1754. . . . . POST-COLONOSCOPY COLORECTAL CANCERS IDENTIFIEDBY POPULATION…(4*) Su1755. . . . . FECAL HEMOGLOBIN CONCENTRATION, AGOOD PREDICTOR…(5*) Su1756. . . . . EFFICACY AND TOLERABILITY OFVARIOUS BOWEL…(2*) Su1757. . . . . COLORECTAL CANCER SCREENING DETECTSTUMOURS AT…(4*)
Su1774. . . . . THE PREVALENCE OF SESSILESERRATED POLYPS…(5*) Su1775. . . . . A MINORITY OF PATIENTSWITH COLORECTAL…(5*) Su1776. . . . . IS UNIVERSAL TUMOR TESTINGFOR LYNCH…(5*) Su1777. . . . . INHERITED SUSCEPTIBILITY TO BILIARYTRACT AND…(3*)| Ambry Genetics provided support in the form of salaries for some of the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Su1778. . . . . SOMATIC APC MOSAICISM CAUSESA HIGH…(2*) Su1779. . . . . UNIQUE FEATURES OF GREM1RELATED HEREDITARY…(5*) Su1780. . . . . INTEGRATION OF CHROMOENDOSCOPY INCOLONOSCOPIC SURVEILLANCE…(5*) Su1781. . . . . PREVALENCE OF GENE MUTATIONSIN PATIENTS…(5*) Su1782. . . . . GENETIC TESTING OF COLORECTALCANCER TISSUE…(5*) Su1783. . . . . BARRETT'S ESOPHAGUS AMONG THEDIFFERENT FAMILIAL…(5*) Su1784. . . . . ENDOSCOPIC FOLLOW UP CANSELECT PATIENTS…(5*) Su1785. . . . . BREAST CANCER ANTI-ESTROGEN RESISTANCE3 (BCAR3)…(2*) Su1786. . . . . UPREGULATED CLAUDIN-2 EXPRESSION ININTESTINAL EPITHELIUM…(2*) Su1787. . . . . EXOSOMES DERIVED FROM COLONCANCER CELLS…(2*) Su1806. . . . . HEDGEHOG-DEPENDENT YAP SIGNALING ACTIVATESSERINE BIOGENESIS…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1807. . . . . MMP-9 MODULATION OF INTESTINALEPITHELIAL TIGHT…(7*)| Crohn's and Colitis Foundation of America (CCFA) Su1808. . . . . NGF ACCELERATES GASTRIC ULCERHEALING IN…(2*) Su1809. . . . . INHIBITION OF Γ-GLUTAMYL TRANSPEPTIDASEATTENUATES HEPATIC…(4*) Su1810. . . . . Δ9-TETRAHYDROCANNABINOL INHIBITS TRANSFORMING GROWTHFACTOR Î’1…(4*) Su1811. . . . . SEPSIS-INDUCED HEPATIC INJURY INRATS IS…(5*) Su1813. . . . . 15-PGDH INHIBITORS PROMOTE HEALINGOF GASTRIC…(2*)| This research was supported by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education(NRF-2015R1D1A1A01059181). Su1814. . . . . EXTRACELLULAR MATRIX FRAGMENTS ASMARKERS OF…(4*) Su1815. . . . . COBALT CHLORIDE COMPROMISES TRANSEPITHELIALBARRIER PROPERTIES…(4*) Su1816. . . . . INTESTINAL EPITHELIAL BARRIER FUNCTIONIS DISRUPTED…(2*) Su1817. . . . . OMENTAL INFARCT MIMICKING COLORECTALCANCER …(5*) Su1818. . . . . DECREASED FEEDING BOUT FREQUENCYIS ATTRIBUTABLE…(5*) Su1819. . . . . ALLYL ISOTHIOCYANATE, A PUNGENTINGREDIENT OF…(2*) Su1820. . . . . LOSS OF MUCOUS LAYERIS THE…(5*)
Su1821. . . . . THE EFFECT OF SMALL-CONDUCTANCECA2+-ACTIVATED K+…(5*) Su1822. . . . . INCREASE OF SMALL INTESTINALPERMEABILITY IN…(2*) Su1823. . . . . L-TRYPTOPHAN DIET ACCELERATES THEHEALING OF…(5*) Su1824. . . . . CHARACTERIZATION AND TARGETING OFTHE HUMAN…(2*) Su1825. . . . . MECP2-MEDIATED EPIGENETIC SILENCING OFMIR-137 CONTRIBUTES…(2*) Su1826. . . . . THE COHESIN SA1 REGULATESEARLY METABOLIC…(2*) Su1827. . . . . EPIGENETIC ALTERATIONS AT DIAGNOSISPREDICT SUSCEPTIBILITY,…(2*) Su1828. . . . . RNA-SEQ OF FORMALIN-FIXED, PARAFFIN-EMBEDDEDINTESTINAL TISSUE…(2*)|(6) Su1829. . . . . HYPOXIA-INDUCIBLE FACTOR 1 ALPHA(HIF1A) STIMULATES…(2*)|(4) Su1830. . . . . P38-Α MITOGEN-ACTIVATED PROTEIN KINASE(MAPK) MEDIATES…(2*) Su1831. . . . . INFLUENCE OF ANTIDEPRESSANTS INPREGNANCY ON…(4*)|(6) Su1832. . . . . METHIONINE CHOLINE-DEPRIVATION IMPACT GROWTHAND VISCERAL…(2*) Su1833. . . . . THE FATTY ACID IMBALANCEOF CYSTIC…(2*) Su1834. . . . . TOPICAL DELIVERY OF IL-10USING A…(4*) Su1835. . . . . RECOMBINANT PRODUCTION OF HUMANBETA-DEFENSIN 2…(3*)| Novozymes provided the hBD2, conducted the immune-
modulatory assays and sponsored the animal studies presented in this abstract. Su1836. . . . . CURCUMA LONGA-DERIVED NANOPARTICLES REDUCE.COLITISAND PROMOTE…(2*) Su1837. . . . . REGULATION OF IL-12P40 BYHIF CONTROLS…(2*)| Aerpio Therapeutics provided a travel grant to attend DDW. Su1838. . . . . Tolerance with Viaskin requiresTGF-β and…(2*)|(4)| DBV Technologies Su1839. . . . . HIGHLY BIOAVAILABLE CURCUMIN INDUCESREGULATORY IMMUNE…(5*) Su1840. . . . . SURFACTANT PROTEIN D ASTHE NOVEL…(5*) Su1841. . . . . CREATING AN ANIMAL MODELOF PERIANAL…(2*) Su1842. . . . . EXACERBATION OF ALLERGIC INFLAMMATIONIN PBMC-ENGRAFTED…(4*) Su1843. . . . . AUTONOMIC-CYTOKINE MECHANISMS OF SACRALNERVE STIMULATION…(2*) Su1844. . . . . GUT MICROBIOME ALTERATIONS ASSOCIATEDWITH AN…(2*)|(6) Su1845. . . . . ANTI-INFLAMMATORY SUPRAMOLECULAR NANOFIBERS TOMODULATE INFLAMMATION…(4*)|(6) Su1846. . . . . NTPDASE8 PROTECTS MICE FROMINTESTINAL INFLAMMATION…(2*)|(4) Su1847. . . . . P2RY6-/- MICE EXHIBIT EXACERBATEDINTESTINAL INFLAMMATION…(4*)|(2) Su1848. . . . . PROTECTIVE EFFECT OF ANOVEL NECROSIS…(5*) Su1849. . . . . TOPICAL THERAPY OF ANTISENSETNF-Α WITH…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1850. . . . . INDIGO NATURALIS AMELIORATES MURINEDEXTRAN SODIUM…(2*) Su1851. . . . . EX VIVO EFFECTS OFSILYMARIN FRACTIONS…(4*) Su1852. . . . . DEFICIENCY OF CCR7 DETERIORATESNON-STEROIDAL ANTI-INFLAMMATORY…(4*) Su1853. . . . . TH1 CELLS PLAY APIVOTAL ROLE…(2*) Su1854. . . . . A NOVEL HYBRID TREATMENTWITH SIMVASTATIN-CONJUGATED…(5*) Su1855. . . . . CARAMEL FOOD COLORANT 2-ACCETYL-4-TETRAHYDROXYBUTYLIMIDAZOLE (THI)…(4*) Su1856. . . . . ORAL ADMINISTRATION OF ACHOLERA VACCINE…(2*) Su1857. . . . . ASTAXANTHIN, A XANTHOPHYLL CAROTENOID,SUPPRESSES THE…(5*) Su1858. . . . . DIGOXIN ATTENUATES MURINE EXPERIMENTALCOLITIS BY…(5*) Su1859. . . . . USEFULNESS OF COMPLEMENT C1QIN ASSESSING…(5*) Su1860. . . . . HELMINTHES DERIVATIVE FOR TREATINGACUTE AND…(3*)|(6)| This study has partially supported by TEVA Company and partially by the Moris family foundation, Los Angeles, USA. Su1861. . . . . EFFICACY AND SAFETY OFSINGLE FECAL…(5*) Su1862. . . . . RISK OF POSTOPERATIVE COMPLICATIONSAMONG INFLAMMATORY…(5*) Su1863. . . . . Evaluation of safety andefficacy of…(2*)|(4) Su1864. . . . . ESCALATION OF THERAPY ININFLAMMATORY BOWEL…(5*)
Su1865. . . . . VEDOLIZUMAB CLINICAL AND POST-MARKETINGSAFETY EXPERIENCE…(3*)| Studies funded by Takeda Pharmaceuticals. Medical writing support sponsored by Takeda Pharmaceuticals Su1866. . . . . UV EXPOSURE AND SKINTYPE ARE…(5*) Su1867. . . . . SHOULD ENDOSCOPIC BALLOON DILATIONBE CONSIDERED…(5*) Su1868. . . . . THE RELATIONSHIP BETWEEN THIOPURINEUSE DURING…(5*) Su1869. . . . . PREOPERATIVE USTEKINUMAB TREATMENT ISNOT ASSOCIATED…(5*) Su1870. . . . . THE INCIDENCE OF CARDIOVASCULAREVENTS IN…(3*)| Financial support for the study was provided by AbbVie. Su1871. . . . . THE EFFECT OF METHOTREXATEON SPERM…(4*)|(3)| ReproSource, Inc. Su1872. . . . . ADVERSE EVENTS WITH USEOF USTEKINUMAB:…(5*) Su1873. . . . . THE IMPACT OF STEROIDUSE ON…(5*) Su1874. . . . . HISTOPLASMOSIS IN THE SETTINGOF BIOLOGIC…(5*) Su1875. . . . . OUTCOMES OF TREATMENT FORLATENT TUBERCULOSIS…(5*) Su1876. . . . . POST-MARKETING EXPERIENCE OF VEDOLIZUMABIN INFLAMMATORY…(3*)| This study was funded by Takeda Pharmaceuticals. Medical writing support sponsored by Takeda Pharmaceuticals. Su1877. . . . . INCIDENCE OF PNEUMONIA ANDOTHER RESPIRATORY…(3*)| This study was funded by Takeda Pharmaceuticals. Medical writing support was sponsored by Takeda.
Su1878. . . . . RAPID INFLIXIMAB INFUSIONS ARESAFE AND…(5*) Su1879. . . . . EBV STATUS AND IMMUNOSUPPRESSANTUSE IN…(4*) Su1880. . . . . PERIOPERATIVE USE OF VEDOLIZUMABIS NOT…(5*) Su1881. . . . . INFLAMMATORY BOWEL DISEASE ANDSKIN CANCER:…(5*) Su1882. . . . . FREQUENCY AND TYPE OFDRUG-RELATED SIDE…(2*) Su1883. . . . . BIOLOGIC AND/OR THIOPURINE USEDURING PREGNANCY…(5*) Su1884. . . . . AUTOIMMUNE PARADOXICAL REACTIONS ININFLAMMATORY BOWEL…(6*) Su1885. . . . . USEFULNESS OF NUDT15 ANDTPMT GENETIC…(5*) Su1886. . . . . THE USE OF TUMORNECROSIS FACTOR…(5*) Su1887. . . . . PREDICTORS OF ACUTE INFLIXIMABINFUSION REACTIONS…(5*) Su1888. . . . . SAFETY OF VEDOLIZUMAB USEIN PATIENTS…(5*) Su1889. . . . . LONG-TERM EFFICACY AND SAFETYOF USTEKINUMAB…(3*)| |Janssen Research & Development, LLC supported this study.) Su1890. . . . . IMPROVED QUALITY OF LIFEWITH ANTI-TNF…(2*) Su1891. . . . . EFFICACY AND SAFETY OFTOPICAL 5-AMINOSALICYLIC…(5*) Su1892. . . . . BIOSIMILAR INFLIXIMAB IN REAL-LIFECROHN'S DISEASE…(5*) Su1893. . . . . EVALUATION OF THE PHARMACOKINETICPROFILES OF…(3*)| |This study was supported by Samsung Bioepis Co., Ltd.)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1894. . . . . SWITCHING FROM REMICADE® TOBIOSIMILAR CT-P13…(5*) Su1895. . . . . NOVEL BIO-ENHANCED CURCUMIN WITHMESALAMINE FOR…(5*) Su1896. . . . . COMPARISON OF THE DURABILITYOF SUBCUTANEOUS…(5*) Su1897. . . . . A COST-EFFECTIVENESS ANALYSIS OFPOST-OPERATIVE PREVENTION…(5*) Su1898. . . . . UTILIZING A MARKOV MODELTO DETERMINE…(5*) Su1899. . . . . A MARKOV MODEL EVALUATINGTHE COST-EFFECTIVENESS…(5*) Su1900. . . . . A COST-EFFECTIVENESS ANALYSIS EVALUATINGTHE ROLE…(5*) Su1901. . . . . EVALUATION OF PHARMACOKINETIC PROFILESOF SB2…(3*)| Samsung Bioepis Co., Ltd. Su1902. . . . . STRUCTURE AND BIOLOGICAL ACTIVITYOF INFLIXIMAB…(3*) Su1903. . . . . LONG TERM OUTCOME OFULCERATIV E.COLI…(5*) Su1904. . . . . APPROPRIATENESS OF CONCOMITANT IMMUNOMODULATORAND BIOLOGIC…(3*)| Abbvie Janssen Takeda Su1905. . . . . OUTCOMES AND ECONOMIC IMPACTOF SWITCHING…(3*)| Abbvie Su1906. . . . . COMBINING PATIENT PREFERENCES ANDCOMPARATIVE EFFECTIVENESS…(2*) Su1907. . . . . PHARMACOLOGIC THERAPIES FOR SEVERESTEROID REFRACTORY…(5*) Su1908. . . . . FIRST-LINE AND SECOND-LINE BIOLOGICSIN THE…(5*)
Su1909. . . . . FIRST-LINE AND SECOND-LINE BIOLOGICAGENTS AND…(5*) Su1910. . . . . COMPARISON OF PHARMACOLOGICAL THERAPIESFOR MILD-MODERATE…(5*) Su1911. . . . . BT-11: A NOVEL LANTHIONINESYNTHETASE C-LIKE…(2*)| We thank the Virginia Biosciences Health and Research Corporation (VBHRC) and the NIH SBIR program (SBIR R43DK097940 and STTR R41DK099027) for funding. Su1912. . . . . COMPARATIVE PERSISTENCE OF BIOLOGICSIN THE…(3*)| The study was completed during my internship at Biogen. The data was provided by Biogen. Su1913. . . . . EFFICACY OF FERRIC CARBOXYMALTOSEIN RELATION…(5*) Su1914. . . . . COMPARATIVE EFFECTIVENESS ANALYSIS OFFLARES, HOSPITALISATIONS,…(3*)| This study was funded by Takeda Pharmaceuticals, Inc. Su1915. . . . . EFFECT OF MAINTENANCE USTEKINUMABON CORTICOSTEROID-FREE…(3*)| |Janssen Research & Development, LLC supported these studies.) Su1916. . . . . EFFICACY OF USTEKINUMAB FORINDUCTION AND…(3*)| These studies were supported by Janssen Research & Development, LLC Su1917. . . . . PHARMACOKINETICS AND EXPOSURE-RESPONSE OFTOFACITINIB IN…(3*)| Pfizer Inc Su1918. . . . . COMPARISON OF RATES OFACTIVE TUBERCULOSIS…(3*)| Janssen Research & Development, LLC supported these studies. Su1919. . . . . TELEMEDICINE FOR PATIENTS WITHINFLAMMATORY BOWEL…(2*) Su1920. . . . . EFFICACY OF FILGOTINIB, ASELECTIVE JAK1…(3*)
Su1921. . . . . EFFECT OF VEDOLIZUMAB TREATMENTON EXTRAINTESTINAL…(3*)|This study was funded by Takeda Development Centre Europe Su1922. . . . . HISTOLOGICAL REMISSION IS PREDICTIVEOF IMPROVED…(3*)|This study was sponsored by Receptos, a wholly owned subsidiary of Celgene. Su1923. . . . . CHARACTERIZATION OF ULCERATIVE.COLITIS PATIENTSIN THE…(3*)| Janssen Research & Development, LLC Su1924. . . . . EFFICACY AND SAFETY OFABRILUMAB (AMG…(3*)|Amgen and AstraZeneca/MedImmune sponsored this study. Su1925. . . . . LONG-TERM SAFETY AND TOLERABILITYOF ORAL…(3*)| Pfizer Inc Su1926. . . . . ADHERENCE TO AN ANTI-INFLAMMATORYDIET PREVENTS…(4*) Su1927. . . . . ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICALACTIVITY AS…(3*)| Roche Su1928. . . . . A PHASE 2-Jan RANDOMIZED,PLACEBO-CONTROLLED, DOUBLE-BLIND…(3*)| Qu Biologics Inc Su1929. . . . . IMPACT OF REAL WORLDHOME-BASED REMOTE…(2*)|(6)| NIH K 23 and CCFA Career Development Grant Su1930. . . . . MAINTENANCE OF CLINICAL EFFECTIN PATIENTS…(3*)| Galapagos NV Su1931. . . . . LONG-TERM EFFECTIVENESS AND SAFETYOF VEDOLIZUMAB…(3*)|Study sponsored by Takeda Pharmaceuticals. Medical writing support of abstract supported by Takeda Pharmaceuticals. Su1932. . . . . MAINTENANCE OF QUALITY OFLIFE IMPROVEMENT…(3*)| Pfizer Inc
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1933. . . . . FILGOTINIB (GLPG0634, GS-6034), AJAK-1 SELECTIVE…(3*)| Galapagos NV, Gilead Sciences Su1934. . . . . LONG-TERM EFFECTIVENESS AND SAFETYOF VEDOLIZUMAB…(3*)| The study was funded by Takeda Development Centre Europe Su1935. . . . . ETROLIZUMAB DEMONSTRATED NO DIFFERENCEAMONG DOSES…(3*)|Roche Su1936. . . . . ETROLIZUMAB TREATMENT LEADS TOEARLY IMPROVEMENT…(3*)| Roche Su1937. . . . . SUBCLINICAL FIBROSIS IN INFLAMMATORYBOWEL DISEASE…(4*) Su1938. . . . . COLONIC TREG LEVELS AREREDUCED IN…(3*)| Roche Su1939. . . . . SUSTAINED REMISSION WITH VEDOLIZUMABIN PATIENTS…(3*)| This study was funded by Takeda Development Centre Europe Ltd. Su1940. . . . . HISTOLOGICAL REMISSION IN UC:AN ANALYSIS…(3*)| Study supported by Janssen Research & Development, LLC Su1941. . . . . ANTI-MICROBIAL ANTIBODIES AND INFLAMMATORYMARKERS ARE…(3*)| Support for this study was provided by Janssen Pharmaceuticals and Prometheus Laboratories under a Cooperative Research and Development Agreement entitled ‘Antimicrobial antibodies as predictors of inflammatory bowel diseases’ NCRADA number NMR-11-3920. Su1942. . . . . THE ANTI-GLYCAN ANTIBODIES AMCAAND ALCA…(1*)|(2) Su1943. . . . . GASTROINTESTINAL INFECTIOUS AGENTS DETECTEDBY BIOFIRE…(4*)|(3)|BÜHLMANN Laboratories AG, Switzerland Su1944. . . . . ULTRASOUND ELASTICITY IMAGING PREDICTSTHERAPEUTIC OUTCOME…(2*)
Su1945. . . . . PROXIMITY EXTENSION ASSAY BASEDPROTEINS SHOW…(2*) Su1946. . . . . COMPARISON OF THE NONINVASIVEBIOMARKER PERFORMANCE…(2*)| Funding: This work was supported by National Natural Science Foundation of China (CN) (81570501,81472311,81330014). Su1947. . . . . OPPORTUNISTIC SCREENING FOR BONEDISEASE USING…(5*) Su1948. . . . . THERAPEUTIC DRUG MONITORING OFBIOSIMILARS OF…(6*) Su1949. . . . . EXPRESSION DATA FROM CROHN'SDISEASE SMALL…(4*) Su1950. . . . . THE SENSITIVITY AND SPECIFICITYOF NON-INVASIVE…(5*) Su1951. . . . . INGESTION OF 100ML AND300ML BLOOD…(4*) Su1952. . . . . DIGITAL HOLOGRAPHIC MICROSCOPY RELIABLYDETECTS FIBROSIS…(5*) Su1954. . . . . DYNAMIC STATE TRANSITION ANALYSIS(DSTA) OF…(4*)|(6) Su1955. . . . . CHARACTERIZATION OF IMMUNE PHENOTYPESAS PREDICTIVE…(4*)|(3)|Takeda Su1956. . . . . ROLE OF CYCLE TIMESOF POLYMERASE…(4*) Su1957. . . . . SERIAL TUBERCULIN SKIN TESTIMPROVES THE…(5*) Su1958. . . . . EFFECTS OF TIME ONURINARY METABOLIC…(4*) Su1959. . . . . DECREASED LEVELS OF CIRCULATIGPROTEIN S…(5*) Su1960. . . . . THE EFFECTS OF GLIAL#NAME? NEUROTROPHIC…(5*)
Su1961. . . . . IL23/MTOR AXIS IN CX3CR1RESIDENTIAL MACROPHAGES…(2*)|(6) Su1962. . . . . TRANSCRIPTOMIC PROFILING OF INTESTINALMACROPHAGES ISOLATED…(4*) Su1963. . . . . INFLAMED INTESTINE-CHIP: MIMICKING THEMUCOSAL MICROENVIRONMENT…(3*)| |Merck & Co, Inc) Su1964. . . . . TGFÎ’ SIGNAILING IN DENDRITICCELLS IS…(2*) Su1965. . . . . RESETTING OF THE MUCOSALT CELL…(6*)|(2) Su1966. . . . . DIFFERENTIAL EFFECTS OF VEDOLIZUMABAND ETROLIZUMAB-S…(2*)|(4)|The etrolizumab surrogate antibody FIB504 was provided by Genentech, San Francisco, CA. The company was neither involved in the conception and conduction of the study nor in the analysis and interpretation of the results. Su1967. . . . . NEONATAL FC RECEPTOR COOPERATESWITH CLASSICAL…(2*) Su1968. . . . . BALANCE OF NLRP3-MEDIATED IL-1Î’AND IL-18…(6*)|(4) Su1969. . . . . MOLECULAR SIGNALING PATHWAY GOVERNINGGPR15 EXPRESSION…(7*) Su1970. . . . . A NOVEL WHOLE BLOODASSAY DETECTS…(6*) Su1971. . . . . DISTINCT PATTERNS OF SHORTCHAIN FATTY…(3*)| Repha GmbH Biologische Arzneimittel Su1972. . . . . DIETARY WHEAT ALPHA-AMYLASE/TRYPSIN INHIBITORSREDUCE INNATE…(4*) Su1973. . . . . GAMMADELTA T CELLS DEFICIENCYIN THE…(4*) Su1974. . . . . TNFAIP3 (A20) IS AKEY PLAYER…(4*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su2005. . . . . GUT MICROBIOTA AND VENDORDIFFERENCES INFLUENCE…(3*)| Biomodels, LLC Su2006. . . . . LOOKING FOR THE MOSTUSEFUL TAXA…(5*) Su2007. . . . . PROFILES OF SMALL INTESTINALMICROBIOTA: POSSIBLE…(3*)| TSUMURA & CO. Su2008. . . . . SUCCESSFUL USE OF PROBIOTICVSL#3 FOR…(5*) Su2009. . . . . GUT MICROBIOTA: PREDICTOR OFSUCCESS IN…(4*) Su2010. . . . . GASTROINTESTINAL MICROBIOTA ACTIVELY MAINTAINSTHE ADULT…(2*) Su2011. . . . . SHARED GUT MICROBIOME DYSBIOSISIN CROHN'S…(2*)|(6) Su2012. . . . . INCREASED PULMONARY CO2 EXCRETIONIN PATIENTS…(3*)| The study was jointly supported by Commonwealth, LLC, and Synthetic Biologics, Inc. Su2013. . . . . DYSBIOSIS OF THE GASTRICMICROBIOTA ALTERS…(4*) Su2014. . . . . BOWEL OBSTRUCTION LEADS TOMICROBIOTA IMBALANCE,…(2*)|(4) Su2015. . . . . JEJUNAL FLORA OF PATIENTSWITH SMALL…(4*) Su2016. . . . . LOSS OF SHORT CHAINFATTY ACID-PRODUCING…(7*) Su2017. . . . . THE ASSOCIATION OF DONORSTOOL CONSISTENCY…(6*)| Niel and Anna Rasmussen Foundation Anna-Maria and Stephen Kellen Foundation Su2018. . . . . THE ASSOCIATION OF STOOLDONOR DIET…(6*) Su2019. . . . . EFFECT OF GUT MICROBIOTAON GLP-1…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su2020. . . . . THE ROLE OF INTESTINALEPITHELIAL VITAMIN…(2*)|(4) Su2021. . . . . GUT MICROBIOME ANALYSIS REVEALSMAJOR DYSBIOSIS…(2*) Su2022. . . . . FECAL MICROBIOTA DIFFERENCES ACCORDINGTO THE…(2*) Su2023. . . . . INFLUENCE OF POTASSIUM-COMPETITIVE ACIDBLOCKERS AND…(5*) Su2024. . . . . THE INTESTINAL DYSBIOSIS FOUNDIN IBD-PATIENTS…(4*) Su2025. . . . . DIETARY FIBER INTAKE ISASSOCIATED WITH…(5*) Su2026. . . . . MOXIBUSTION MODULATES THE GUTMICROBIOTA IN…(4*) Su2027. . . . . THE INFLUENCE OF HELICOBACTERPYLORI ERADICATION…(2*)|(4) Su2028. . . . . CHARACTERISTICS OF PATIENTS UNDERGOINGFECAL MICROBIOTA…(5*) Su2029. . . . . EFFECTS OF LIRAGLUTIDE ONGASTRIC EMPTYING,…(2*) Su2030. . . . . BAR130, A HYODEOXYCHOLIC ACIDDERIVATIVE AS…(3*)| BAR Pharmaceuticals, Italy Su2031. . . . . HUMANIZATION OF A GASTRICINHIBITORY POLYPEPTIDE…(4*) Su2032. . . . . A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED,16-WEEK TRIAL…(2*) Su2033. . . . . ARGON PLASMA COAGULATION ISEFFECTIVE IN…(4*) Su2034. . . . . MORPHOLOGICAL BRAIN ALTERATIONS ANDCHANGES IN…(2*)|(4)
Su2035. . . . . IMPROVEMENT IN GLUCOSE METABOLISMAFTER BARIATRIC…(5*) Su2036. . . . . EFFECT OF LAPAROSCOPIC SLEEVEGASTRECTOMY ON…(4*) Su2037. . . . . MOST GASTRIC BYPASS PATIENTSWITH ABNORMAL…(5*) Su2038. . . . . SURGICAL INTERVENTION OF ORTHOPEDICCONDITIONS DOES…(4*) Su2039. . . . . TRANSORAL OULET REDUCTION WITHFULL THICKNESS…(5*) Su2040. . . . . INTRAGASTRIC BALLOON TREATMENT FOROBESITY: MEDIUM,…(5*) Su2041. . . . . ENDOSCOPIC MANAGEMENT OF GASTRICLEAKS AFTER…(5*) Su2042. . . . . AUGMENTATION OF MEAL-RELATED SYMPTOMSFOLLOWING PLACEMENT…(4*)|(2) Su2043. . . . . OBESITY TREATMENT USING NONADJUSTABLE INTRAGASTRIC…(5*) Su2044. . . . . IMPROVEMENTS OF LIVER ANDGLYCAEMIC PARAMETERS…(4*)|(2) Su2045. . . . . COMMON BILE DUCT DILATIONAFTER BARIATRIC…(5*) Su2046. . . . . THE IMPACT OF INTRAGASTRICBALLOONS ON…(4*) Su2049. . . . . EXERCISE-DERIVED MYOKINES ALTER THEFATTY ACID…(2*) Su2050. . . . . GASTRIC CANCER AND O-GLCNACYLATION …(5*) Su2051. . . . . HUMAN TRANSCRIPTOME ARRAY REVEALSASSOCIATION OF…(4*)
Su2052. . . . . DUAL INHIBITOR SENSITIZES PANCREATICCANCER CELLS…(2*)|(4) Su2053. . . . . USE OF A COMBINATIONOF LENTIVIRUS…(4*) Su2054. . . . . DEVELOPMENT OF IPSC-BASED ΓΔT-CELLIMMUNOTHERAPY FOR…(2*) Su2055. . . . . BLOCKING HYALURONIC ACID BINDINGTO TLR4…(2*) Su2056. . . . . ARE THERE PROGNOSTIC PARAMETERSFOR THE…(4*)| Rashid Hussain Trust, Kuala Lumpur, Malaysia Su2057. . . . . REAL TIME PHENOMENON ONNUCLEUS &…(5*) Su2058. . . . . DEVELOPMENT AND RELIABILITY OFTHE NEW…(5*) Su2059. . . . . LOCATION AND KUDO PITPATTERN REFLECT…(5*) Su2060. . . . . TREAT TO TARGET INCROHN'S DISEASE:…(5*) Su2061. . . . . CROHN'S DISEASE OF THETERMINAL ILEUM:…(5*) Su2062. . . . . PREDICTION OF TREATMENT RESPONSEIN CROHN'S…(5*) Su2063. . . . . WATER EXCHANGE (WE) SIGNIFICANTLYRAISES ADENOMA…(2*)|(4) Su2064. . . . . ULTRASONOGRAPHY WITH COLOR DOPPLERANALYSIS IN…(4*) Su2065. . . . . POINT OF CARE ULTRASOUNDACCURATELY DISTINGUISHES…(5*) Su2066. . . . . GASTROINTESTINAL PROBLEMS IN CHILDRENENROLLED IN…(4*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su2067. . . . . AGE-DEPENDENT VALUES OF FECALCALPROTECTIN IN…(6*)| CF Australia Research Trust Grant Su2068. . . . . DETERMINING THE AGE-RELATED LEVELSOF FECAL…(6*)| CF Australia Research Trust Grant Su2069. . . . . PREVALENCE OF KNOWN CONGENITALSUCRASE-ISOMALTASE DEFICIENCY…(3*)| QOL Medical, LLC sponsored this study. Su2070. . . . . LOSS OF NHE8 EXPRESSIONIMPAIRS CRYPT…(2*) Su2071. . . . . HYPERTENSION AND AGING AREASSOCIATED WITH…(5*) Su2072. . . . . AGE-RELATED CHANGES IN ABDOMINALPAIN IN…(3*)| This abstract is based on two studies, an intervention study and the Maastricht IBS cohort. Both studies were partly funded by Top Institute of Food and Nutrition. This is a public private partnership of science, industry and government conducting strateg Su2073. . . . . DIAGNOSING THE CHILD WITHDYSPHAGIA TO…(5*) Su2074. . . . . EZH2 INHIBITION PREVENTS AGE-RELATEDSENESCENCE OF…(2*)|(4) Su2075. . . . . CTRC G60G VARIANT ISCOMMON IN…(2*)|(6) Su2076. . . . . FECAL MICROBIOTA TRANSPLANTATION INCHILDREN DOES…(2*) Su2077. . . . . PREVALENCE OF ROME IVFUNCTIONAL GASTROINTESTINAL…(6*) Su2078. . . . . PREVALENCE OF FUNCTIONAL GASTROINTESTINALDISORDERS IN…(6*) Su2079. . . . . IMPAIRED POSTPRANDIAL COLONIC RESPONSEIN THE…(5*) Su2080. . . . . THE PROGNOSTIC VALUE OFMANOMETRY TESTING…(5*)
Mo1648. . . . . POLY(I:C) REGULATES THE INTESTINALBARRIER FUNCTION…(5*) Mo1649. . . . . RIP3, A REGULATOR OFNECROPTOSIS, PROMOTES…(5*) Mo1650. . . . . DIPOTASSIUM GLYCYRRHIZATE MODULATES GENESWITH A…(5*) Mo1651. . . . . INACTIVATION OF EPHRINA1/EPHA2 KINASEATTENUATES LIPOPOLYSACCHARIDE-INDUCED…(4*)| Funding: This study was supported by grant from the National Natural Science Foundation of China (NSFC 81570486). Mo1652. . . . . IMPACT OF PROINFLAMMATORY CYTOKINESAND MESALAMINE…(3*)|(4)| This work was supported by an unrestricted research grant by Shire to D. C. Baumgart. The grants and contracts have been checked by the legal Department of Charité Universitätsmedizin (Berlin, Germany) and have been approved by the directorate of the Facu) Mo1653. . . . . PATIENTS IN REMISSION AREMORE LIKELY…(6*) Mo1654. . . . . NATURAL HISTORY OF DYSPLASIAAND COLORECTAL…(5*) Mo1655. . . . . CORRELATION BETWEEN PHYSICIAN ANDPATIENT DISEASE…(3*)| AbbVie Mo1656. . . . . FACTORS IMPACTING PATIENT REPORTEDHEALTH-RELATED QUALITY…(2*) Mo1657. . . . . CHOLECYSTECTOMY FOR BILIARY DYSKINESIA:CAN WE…(5*) Mo1658. . . . . FREQUENT FLYERS'� IN EMERGENCYDEPARTMENTS: WHY…(5*) Mo1659. . . . . EFFECT OF ADALIMUMAB DOSEESCALATION ON…(3*)| AbbVie Mo1660. . . . . EFFECT OF ADALIMUMAB ONEXTRAINTESTINAL MANIFESTATIONS…(3*)| AbbVie
Mo1661. . . . . ADALIMUMAB LONG-TERM EFFECTIVENESS INADALIMUMAB-NAÃ�VE PATIENTS…(3*)| AbbVie Mo1662. . . . . PRESENCE OF ANGIODYSPLASIA ISASSOCIATED WITH…(5*) Mo1663. . . . . ADALIMUMAB EFFICACY AND SAFETYBY DISEASE…(3*)| AbbVie Mo1664. . . . . DOES PERORAL ENDOSCOPIC MYOTOMY(POEM) IMPROVE…(5*) Mo1665. . . . . THE WAITING ROOM QUESTIONNAIRE:VALIDATION OF…(5*) Mo1666. . . . . DIFFERENCES IN DEMOGRAPHIC ANDSYMPTOM-RELATED CHARACTERISTICS…(3*)| Allergan plc and Ironwood Pharmaceuticals Mo1667. . . . . UNDERSTANDING SYMPTOM BURDEN ANDATTITUDES IN…(3*)| This study was supported by Allergan plc. Mo1668. . . . . EFFECTS OF PATIENT EDUCATIONON ADHERENCE…(5*) Mo1669. . . . . ASSOCIATION BETWEEN PHARMACOKINETICS OFADALIMUMAB AND…(5*) Mo1670. . . . . DISPARITIES IN THE INTEGRATIONOF MENTAL…(4*) Mo1671. . . . . INFLAMMATORY BOWEL DISEASE (IBD)PATIENT EXPERIENCES…(4*) Mo1672. . . . . COMPARATIVE SHORT AND LONGTERM EFFICACY…(5*) Mo1673. . . . . FACTORS ASSOCIATED WITH ANXIETYABOUT COLONOSCOPY:…(2*) Mo1674. . . . . PREDICTORS OF SELF-EFFICACY INMANAGEMENT OF…(5*) Mo1675. . . . . EFFECTS OF BEHAVIORAL TREATMENTON ANXIETY…(1*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1676. . . . . PREDICTORS OF IN-HOSPITAL MORTALITYIN PATIENTS…(5*) Mo1677. . . . . SALIVARY CORTISOL AS ABIOMARKER OF…(5*) Mo1678. . . . . PATIENT FACTORS AS PREDICTORSOF BOWEL…(4*) Mo1679. . . . . RANDMIZED, OPEN-LABEL TRIAL COMPARINGEFFICACYOF BURDOCK…(5*) Mo1680. . . . . THIOPURINES IS A BETTEROPTION OVER…(5*) Mo1681. . . . . A QUALITATIVE ANALYSIS OFPATIENT ATTITUDES…(2*) Mo1682. . . . . DEVELOPMENT OF A COREOUTCOME SET…(5*) Mo1683. . . . . DEVELOPMENT OF A COREOUTCOME SET…(5*) Mo1684. . . . . NUTRITIONAL HABITS AND FODMAPSIN RELATION…(4*) Mo1685. . . . . LOW-FODMAP DIET RESULTED EFFECTIVEIN RELIEVING…(5*) Mo1686. . . . . FACTORS THAT PREDICT INTESTINALRESECTION IN…(5*) Mo1687. . . . . TOWARDS A PATIENT-REPORTED OUTCOMESBASED SEVERITY…(3*)| This study was supported by Allergan plc. Mo1688. . . . . THE SAFETY OF ENDOSCOPISTDIRECTED NURSE…(5*) Mo1689. . . . . A PROSPECTIVE COHORT STUDYTO ASSESS…(5*) Mo1690. . . . . PHENOTYPIC CHARACTERISTICS CAN PREDICTTHE NEED…(5*) Mo1691. . . . . PERCEIVED UTILITY OF SOCIALMEDIA AND…(5*)
Mo1707. . . . . THE ROLE OF PROTEINO-GLCNACYLATION IN…(5*) Mo1708. . . . . THE Α7 NICOTINIC ACETYLCHOLINERECEPTOR AGONIST…(5*) Mo1709. . . . . A ROLE OF IRHOM2IN CHRONIC…(5*) Mo1710. . . . . SUPPRESSION OF EXPERIMENTAL ULCERATIVECOLITIS BY…(4*)|(3)| Sterna Biologicals Mo1711. . . . . A MECHANISM OF ACTIONFOR CYCLOSPORINE…(4*) Mo1712. . . . . BALANCING JAK/STAT-SIGNALING WITH TOFACITINIBIN MONOCYTES…(3*)| EUROPE ASPIRE 2014 Research Award (60.000 €) Mo1713. . . . . THE ROLE OF THERS8005161 POLYMORPHISM…(2*) Mo1714. . . . . EXPANSION OF IL-23 RECEPTORBEARING TNFR2+…(2*) Mo1715. . . . . ROLE OF INNATE LYMPHOIDCELLS IN…(5*) Mo1716. . . . . MATERNAL IBD AND IBDTHERAPIES MAY…(4*) Mo1717. . . . . AN ABERRANT SUMOYLATION DEPENDENTSUB-PROGRAMMING OF…(5*) Mo1718. . . . . THE SYSTEMIC INFLAMMATORY RESPONSETO CLOSTRIDIUM…(4*) Mo1719. . . . . Systemic TNF-α Reduction byBlocking IgE-Mediated…(3*)| STC Biologics, Cambridge, MA Mo1720. . . . . UTILITY OF SERUM CYTOKINEANALYSIS BY…(2*) Mo1721. . . . . SERUM POLYUNSATURATED FATTY ACIDSCORRELATE WITH…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1722. . . . . CIRCULATING INTEGRIN ALPHA4/BETA7+ LYMPHOCYTESTARGETED BY…(2*)|(4) Mo1723. . . . . PROTEIN PROFILING OF CIRCULATINGINFLAMMATORY MARKERS…(2*) Mo1724. . . . . ROLE OF IL-38 ANDITS ANTAGONIST…(4*) Mo1725. . . . . MURIN E.COLITIS INDUCED INFLAMMATORYVASCULAR LEAK…(4*) Mo1726. . . . . EVALUATION OF THE PRO-INFLAMMATORYER STRESS…(2*)|(4) Mo1727. . . . . THE ACTIVATION OF ADENOSINEA3 RECEPTOR…(2*)| Supported by Science and Technology Innovation Committee of Shenzhen City (No. JCYJ20150331142757394) and Natural Science Foundation of Guangdong Province (No. 2016A030313009) Mo1728. . . . . DEEP PROFILING OF INTEGRINÎ’7 THROUGHOUT…(3*)| Genentech, Inc. Mo1729. . . . . ANTI-INFLAMMATORY EFFECTS OF SMAC-MIMETICBV6 ON…(4*)|(6) Mo1730. . . . . HIGHER EXPRESSION OF MIP-1Î’AND IL23…(4*) Mo1731. . . . . EXPRESSION OF TRANSIENT RECEPTORPOTENTIAL CHANNELS…(2*) Mo1732. . . . . PLACENTAL MADCAM1 EXPRESSION ANDPOTENTIAL CONSEQUENCES…(3*)| Takeda Mo1733. . . . . ABP 501:00:00 MATCHING THECRITICAL FUNCTIONS…(3*)| Amgen, Inc. Mo1734. . . . . EXERCISE-INDUCED MYOKINES IMPROVE INTESTINALWOUND HEALING:…(4*) Mo1735. . . . . CALCIUM-SENSING RECEPTOR REGULATION OFTIGHT JUNCTION…(2*)
Mo1736. . . . . THE ROLE OF EGCGON FORMATION…(4*) Mo1737. . . . . THE PHARMACOLOGICAL PROFILE OFTOP1288, A…(3*)| Topivert Pharma Mo1738. . . . . BINDING PROPERTIES OF HUMANTLR-9 RECEPTOR…(3*)| Index Pharmaceuticals Mo1739. . . . . IL-10 INDUCTION PROPERTIES OFTHE TLR-9…(3*)| Index Pharamceuticals Mo1740. . . . . POSITIVE ASSOCIATION BETWEEN LEPTINSERUM LEVELS…(1*)|(2) Mo1741. . . . . INCREASED BASELINE TNF-DRIVEN PATHWAYSOBSERVED IN…(2*)|(3)| Grant support: AbbVie, MSD and Takeda Mo1742. . . . . PHOSPHO-FLOW CYTOMETRY: A METHODFOR INVESTIGATING…(3*)| Topivert Pharma Ltd Mo1743. . . . . SERUM CYTOKINE PROFILE ANDIGG4 LEVELS…(5*) Mo1744. . . . . MADCAM1 EXPRESSION IN INTESTINALLAMINA PROPRIA…(5*) Mo1745. . . . . UTILIZING NAILFOLD CAPILLAROSCOPY TOMONITOR DISEASE…(5*) Mo1746. . . . . SERUM MARKER PANEL FOREARLY DETECTION…(2*)|(4) Mo1747. . . . . CAN MRE BE USEDAS AN…(5*) Mo1748. . . . . A MULTICENTER STUDY TOVALIDATE MAGNETIC…(3*)| Genentech, Inc. Mo1749. . . . . TRANSMURAL HEALING IS BETTERTHAN MUCOSAL…(5*) Mo1750. . . . . DISAGREEMENT AMONG GASTROENTEROLOGISTS INTHE ENDOSCOPIC…(5*)
Mo1751. . . . . DETECTION OF CALPROTECTIN ININFLAMMATORY BOWEL…(5*) Mo1752. . . . . DIPEPTIDYL PEPTIDASE 4 (DPP-4):AN EMERGING…(7*) Mo1753. . . . . FECAL IMMUNOCHEMICAL TEST ANDFECAL CALPROTECTIN…(5*) Mo1754. . . . . LONGITUDINAL EVALUATION WITH CAPSULEENDOSCOPY FOR…(3*)| This study was funded by Medtronic Mo1755. . . . . PATIENTS WITH UC ANDCONCOMITANT PSC…(4*) Mo1756. . . . . ASSESSMENT OF DISEASE ACTIVITYAND PREDICTING…(4*) Mo1757. . . . . CENTRALLY-DETERMINED STANDARDIZATION OF FLOWCYTOMETRY METHODS…(5*) Mo1758. . . . . TREAT TO TARGET: RECOMMENDATIONSIN ULCERATIVE…(5*) Mo1759. . . . . FAECAL CALPROTECTIN AND MAGNETICRESONANCE IMAGING…(5*) Mo1760. . . . . HIGH FECAL CALPROTECTIN LEVELSIN ULCERATIVE.COLITIS…(4*) Mo1761. . . . . FECAL CALPROTECTIN CORRELATES TOENDOSCOPIC AND…(5*) Mo1763. . . . . FECAL CALPROTECTIN VERSUS FECALIMMUNOCHEMICAL TEST…(5*) Mo1764. . . . . DUBLIN (DEGREE OF ULCERATIVECOLITIS BURDEN…(5*) Mo1765. . . . . ADALIMUMAB THERAPY RATHER THANAZATHIOPRINE AND…(4*) Mo1766. . . . . RATES OF AND CLINICALPREDICTORS OF…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1767. . . . . LOW-DOSE METRONIDAZOLE IS ASSOCIATEDWITH A…(4*)|(2)| This research was supported in part by the NIH NIDDK grant #T35DK062719-29. Mo1768. . . . . DISEASE DURATION OF ULCERATIVE.COLI TIS…(5*) Mo1769. . . . . ROLE OF PET-CT TOASSESS DISEASE…(5*) Mo1770. . . . . IDENTIFICATION OF NOVEL SERUMBIOMARKERS FOR…(5*) Mo1771. . . . . FAECAL DIVERSION IS ASSOCIATEDWITH A…(4*) Mo1772. . . . . ALBUMIN AS A PROGNOSTICMARKER FOR…(5*) Mo1773. . . . . RAPIDITY OF ONSET OFRESPONSE TO…(3*)| The design, study conduct, and financial support for the clinical trial was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. Mo1774. . . . . ELEVATED C-REACTIVE PROTEIN LEVELDURING CLINICAL…(5*) Mo1775. . . . . CLINICAL, ENDOSCOPIC, AND HISTOLOGICGI MANIFESTATIONS…(2*) Mo1776. . . . . SERUM SEPSIS MARKERS SOLUBLECD14 SUBTYPE…(4*) Mo1777. . . . . FECAL LACTOFERRIN IS CORRELATEDWITH THE…(3*)| TechLab Inc. Blacksburg, VA Mo1778. . . . . POST-OPERATIVE COMPLICATIONS IN ELDERLY-ONSETINFLAMMATORY BOWEL…(5*) Mo1779. . . . . MULTICENTRE COHORT STUDY TOEVALUATE THE…(4*) Mo1780. . . . . SERUM CHITINASE-3-LIKE PROTEIN 1(YKL-40) PREDICTS…(2*)|(3)
Mo1781. . . . . RISK OF MALIGNANT ANDNON-MALIGNANT COMPLICATIONS…(5*) Mo1782. . . . . NOVEL DIAGNOSTIC TOOLS TODIFFERENTIATE C.…(3*)| TechLab Inc. Blacksburg, VA Mo1783. . . . . NON ALCOHOLIC FATTY LIVERDISEASE IN…(5*) Mo1784. . . . . ABDOMINAL PAIN MODIFIERS ININFLAMMATORY BOWEL…(5*) Mo1785. . . . . RATES AND PREDICTORS OFSURGERY IN…(4*)|(3)| Statistical analyses were conducted at the University of California, San Diego and funded in part by Takeda Pharmaceuticals Mo1786. . . . . IL-26 GENETIC POLYMORPHISMS IMPAIRCYTOKINE RESPONSE…(6*) Mo1787. . . . . INCIDENCE OF AND RISKFACTORS FOR…(5*) Mo1788. . . . . EFFICACY AND SAFETY OFENDOSCOPIC BALLOON…(5*) Mo1789. . . . . VENOUS THROMBOEMBOLISM REMAINS ASIGNIFICANT COMPLICATION…(5*) Mo1790. . . . . OBESITY IS ASSOCIATED WITHINCREASED RISK…(5*) Mo1791. . . . . RISK OF TUBERCULOSIS ININFLAMMATORY BOWEL…(4*) Mo1792. . . . . IBD PATIENTS WITH SEVEREDISEASE ARE…(5*) Mo1793. . . . . SURGERY FOR ULCERATIVE.COLITIS INGERIATRIC PATIENTS…(5*) Mo1794. . . . . SYMPTOMATIC VENOUS THROMBOEMBOLISM ISA RARE…(5*) Mo1795. . . . . CORTICOSTEROIDS MAY INFLUENCE OUTCOMESIN INFLAMMATORY…(4*)
Mo1796. . . . . IRON-DEFICIENCY WITHOUT ANEMIA INCROHN'S DISEASE:…(5*) Mo1797. . . . . RISK FACTORS FOR THEDEVELOPMENT OF…(4*) Mo1798. . . . . LOSS OF TOLERANCE TOTHE NOVEL…(1*)|(2) Mo1799. . . . . NEW HUMAN GUT XENOGRAFTMOUSE MODEL…(7*) Mo1800. . . . . PERSISTENT SYMPTOMS, CRP ELEVATIONAND TREATMENT…(5*) Mo1801. . . . . RISK FACTORS FOR VITAMIND DEFICIENCY…(5*) Mo1802. . . . . EARLY ONSET OF DISEASEAND INCREASED…(5*) Mo1803. . . . . THE PRESENCE OF OPERATIVECOMPLICATIONS INCREASES…(2*) Mo1804. . . . . RISK FACTORS ASSOCIATED WITHINCREASED LENGTH…(5*) Mo1805. . . . . SYSTEMATIC REVIEW AND META-ANALYSIS:RISK OF…(5*) Mo1806. . . . . OUTCOME OF ENDOSCOPIC RESECTIONOF LARGE…(5*) Mo1807. . . . . CROHN'S DISEASE DIAGNOSIS AFTERPROCTOCOLECTOMY AND…(5*) Mo1808. . . . . A RETROSPECTIVE ANALYSIS OFCLOSTRIDIUM DIFFICILE…(5*) Mo1809. . . . . NATURAL HISTORY OF PERIANALCROHN'S DISEASE…(5*) Mo1810. . . . . VARIATIONS IN HEALTH INSURANCESPOLICIES REGARDING…(5*) Mo1811. . . . . IMPROVING HEALTH MAINTENANCE INVETERANS WITH…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1812. . . . . MANAGEMENT OF IRON DEFICIENCYANEMIA WITHIN…(3*)| Luitpold Pharmaceuticals Mo1813. . . . . MULTI-CENTER INTERVENTION TO IMPROVEDOCUMENTED REPORTING…(4*) Mo1814. . . . . TARGETED PHYSICIAN EDUCATION ANDSTANDARDIZING DOCUMENTATION…(5*) Mo1815. . . . . MULTIFACETED TARGETED INTERVENTIONS IMPROVETHE DOCUMENTED…(4*) Mo1816. . . . . A POPULATION-BASED STUDY EVALUATINGAN INTEGRATED…(2*)|(6)|Saskatchewan Health Research Foundation (SHRF), Crohn's and Colitis Canada (CCC), and Canadian Foundation for Innovation Mo1817. . . . . INFLAMMATORY BOWEL DISEASE RELATED30 DAYS…(5*) Mo1818. . . . . HOW ARE PATIENT OUTCOMESIMPACTED BY…(5*) Mo1819. . . . . PREDICTING 30-DAY READMISSION RATEIN INFLAMMATORY…(5*) Mo1820. . . . . REAL-WORLD PRESCRIPTION DRUG UTILIZATIONAND COSTS…(2*) Mo1821. . . . . FAECAL CALPROTECTIN DIFFERENTIALLY PREDICTSPOSTOPERATIVE ENDOSCOPIC…(5*) Mo1822. . . . . VARIATION IN ANNUAL RATEOF STEROID…(4*) Mo1823. . . . . DEMOGRAPHIC AND HEALTHCARE FACTORSASSOCIATED WITH…(4*)|(6) Mo1824. . . . . COST BENEFIT ANALYSIS OFRAPID INFLIXIMAB…(5*) Mo1825. . . . . INDIVIDUALS AT HIGH-RISK FORAN ACUTE…(5*)
Mo1826. . . . . HEALTH INSURANCE STATUS OFHOSPITALIZED PATIENTS…(5*) Mo1827. . . . . QUANTIFYING THE POTENTIAL CLINICALIMPACT OF…(5*) Mo1828. . . . . MALADAPTIVE COPING, SELF-EFFICACY ANDPATIENT REPORTED…(5*) Mo1829. . . . . IMPACT OF PATIENT REPORTEDOUTCOMES, COPING…(5*) Mo1830. . . . . AFFECTIVE SPECTRUM DISORDERS SIGNIFICANTLYINFLUENCE TOTAL…(5*) Mo1831. . . . . CAUSES AND CONSEQUENCES OFAFFECTIVE SPECTRUM…(5*) Mo1832. . . . . FEMALE GENDER, SOMATIZATION ANDPRESENCE OF…(1*) Mo1833. . . . . HEALTH MAINTENANCE DIFFERENCES INPATIENTS WITH…(5*) Mo1834. . . . . PSYCHO-SOCIAL PREDICTORS OF NONCOMPLIANCEWITH CHRONIC…(6*) Mo1835. . . . . IMPROVED MATERNAL AND NEONATALOUTCOMES IN…(5*) Mo1836. . . . . INCREASED HEALTH CARE RESOURCEUTILIZATION IN…(5*) Mo1837. . . . . TRANSITION READINESS AND COLLEGEADJUSTMENT IN…(3*)| |Abbvie) Mo1838. . . . . NATIONAL SURVEY OF INFLAMMATORYBOWEL DISEASE…(4*)|(6) Mo1839. . . . . SELF-REPORT IS NOT ASENSITIVE METHOD…(6*)|(2) Mo1840. . . . . RESILIENCE IS ASSOCIATED WITHLOWER RATES…(5*) Mo1841. . . . . LOOKING BEYOND THE PATIENT:THE IMPACT…(5*)
Mo1842. . . . . THE IMPACT OF SOMATICVS COGNITIVE…(5*) Mo1843. . . . . NUTRITIONAL PROFILE OF PATIENTSWITH CROHN'S…(5*) Mo1844. . . . . DEVELOPMENT AND PILOTING OFA COGNITIVE-BEHAVIORAL…(6*) Mo1845. . . . . POOR SLEEP QUALITY INCROHN'S DISEASE…(5*) Mo1846. . . . . EVALUATION OF KNOWLEDGE TRANSLATIONRESOURCES FOR…(2*) Mo1847. . . . . ILLNESS PERCEPTION IN IBDPATIENTS: A…(5*) Mo1848. . . . . SLEEP QUALITY IN PATIENTSWITH INACTIVE…(4*) Mo1849. . . . . THE IMPACT OF TRANSITIONTO ADULT…(3*) Mo1850. . . . . AN ANALYSIS OF SOCIALMEDIA USE…(5*) Mo1851. . . . . MIR-646 REGULATES CELL PROLIFERATION,MIGRATION AND…(2*) Mo1852. . . . . ZINC-FINGER PROTEIN 471 FUNCTIONSAS A…(4*) Mo1853. . . . . SERINE THREONINE KINASE 17AREGULATES INVASION…(2*) Mo1854. . . . . CROSSTALK BETWEEN INSULIN/IGF-1 RECEPTORAND G…(2*) Mo1855. . . . . MICRORNA-155 IS REGULATED BYAPC MUTATIONS…(6*) Mo1856. . . . . PERIOSTIN PROMOTES MALIGNANT POTENTIALBY INDUCTION…(2*) Mo1857. . . . . AXL UPREGULATES C-MYC EXPRESSION:A NOVEL…(2*)|(2)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1859. . . . . UNRAVELING THE SERRATED NEOPLASIAPATHWAY: IMMUNOHISTOCHEMISTRY…(6*) Mo1860. . . . . THE PROTECTIVE ROLE OFVITAMIN D3…(4*) Mo1861. . . . . LONG NONCODING RNA NEAT1MEDIATES GASTRIC…(2*) Mo1862. . . . . TARGETED LOSS OF FORKHEADBOX A1…(2*)|(4) Mo1864. . . . . HIGH FREQUENCY OF RNF43R117H MISSENSE…(4*) Mo1865. . . . . WELL-BEING IN A DOUBLE-BLINDRANDOMIZED CLINICAL…(3*)| Bioprojet Pharma France Mo1866. . . . . DIARRHEA ASSOCIATED SYMPTOMS INA DOUBLE-BLIND…(3*)| Bioprojet Pharma France Mo1867. . . . . STUDY OF SMALL-INTESTINAL MUCOSALINJURY IN…(5*) Mo1868. . . . . EVALUATION OF THE DIAGNOSTICAND PROGNOSTIC…(5*) Mo1869. . . . . NOVEL PROTOCOL TO TESTTHE IMPACT…(4*)|(3)|Biocodex Mo1870. . . . . CLINICAL SYMPTOMS AND GASTROINTESTINALHISTOPATHOLOGIY IN…(5*) Mo1871. . . . . EFFICACY AND SAFETY OF5-AMINOSALICYLIC ACID…(2*)| Ministry of Food and Drug Safety Mo1872. . . . . UPPER AND LOWER GASTROINTESTINALENDOSCOPIC FINDINGS…(5*) Mo1873. . . . . IMPACT OF ENDOSCOPIC CLASSIFICATIONDICATION…(5*) Mo1874. . . . . NATURAL HISTORY OF SYMPTOMATICUNCOMPLICATED DIVERTICULAR…(5*) Mo1875. . . . . FECAL MICROBIOTA, FECAL ANDURINARY METABOLIC…(5*)
Mo1876. . . . . INFLUENCE OF CYTOCHROME P4502C19 POLYMORPHISMS…(5*) Mo1877. . . . . A ROLE FOR SALIVARYPEPTIDES IN…(2*) Mo1878. . . . . CHILDHOOD AND ADULT IRRITABLEBOWEL SYNDROME…(2*) Mo1879. . . . . THE ROLE OF SMALLINTESTINAL BACTERIAL…(5*) Mo1880. . . . . THE EFFECT OF SEVERELYREDUCED KIDNEY…(5*) Mo1881. . . . . GASTROINTESTINAL AND EXTRAINTESTINAL SYMPTOMSOCURRING DURING…(5*) Mo1882. . . . . REBLEEDING RATE AND RELATEDRISK FACTORS…(5*) Mo1883. . . . . RISK FACTORS OF RENALDYSFUNCTION CAUSED…(1*) Mo1884. . . . . SMALL BOWEL BACTERIAL OVERGROWTH(SIBO) IN…(5*) Mo1885. . . . . USE OF INFLIXIMAB INTHE TREATMENT…(5*) Mo1886. . . . . TIME TRENDS OF THEPREVALENCE OF…(5*) Mo1887. . . . . ENTEROPATHY ASSOCIATED WITH RITUXIMAB-INDUCEDHYPOGAMMAGLOBINEMIA …(5*) Mo1888. . . . . ANTI-PD-1 INDUCED COLITIS: ACASE SERIES…(5*) Mo1889. . . . . RESOLUTION OF CHRONIC DIARRHEAIN PEDIATRIC…(3*)| LiveLeaf. Inc. Mo1890. . . . . FECAL MICROBIOME IN PARENTERALNUTRITION DEPENDENT…(2*)|(4) Mo1891. . . . . AN AMINO ACID-BASED ORALREHYDRATION
SOLUTION…(3*)|(4)| Entrinsic Health Solutions, LLC Mo1892. . . . . MAGNETIC RESONANCE ENTEROGRAPHY DISTINGUISHESINTESTINAL TUBERCULOSIS…(5*) Mo1893. . . . . NEW INDICATIONS FOR TEDUGLUTIDEIN TEMPORARY…(5*) Mo1894. . . . . PREVALENCE OF COLONIC DIVERTICULOSISIN PATIENTS…(5*) Mo1895. . . . . NICKEL ALLERGIC CONTACT MUCOSITIS:DUODENAL HISTOLOGICAL,…(4*) Mo1896. . . . . ELEVATED CLINICAL INFLAMMATORY MARKERSAND CYTOKINE…(5*) Mo1897. . . . . DIETARY EMULSIFIER POLYSORBATE-80 INCREASESTHE GENUS…(5*) Mo1898. . . . . VONOPRAZAN, A NOVEL ACTIVEPOTASSIUM-COMPETITIVE ACID…(4*) Mo1899. . . . . OKADAELLA GASTROCOCCUSIKE BACTERIA POSITIVEREACTIVE GASTROPATHY…(5*) Mo1900. . . . . THE EFFECTS OF FOURWEEKS PECTIN…(3*)| This study has been funded bij Top Instutute of Food and Nutrition. TI Food and Nutrition is a public private partnership of science, industry and government conducting strategic research in food and nutrition. Mo1901. . . . . INULIN AND STREPTOCOCCUS SALIVARIUSREDUCE HALITOSIS…(4*) Mo1902. . . . . ANTIBACTERIAL RESISTANCE AGAINST MRSAORAL INFECTION…(5*) Mo1903. . . . . IMPROVED URINARY TRACT INFECTIONSWITH FECAL…(5*) Mo1904. . . . . A NEW MOUSE MODELFOR HUMAN…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1905. . . . . UTILITY OF ANTIGEN DETECTIONOF HELICOBACTER…(5*) Mo1906. . . . . THIRTY DAYS OF MULTI-STRAINPROBIOTIC SUPPLEMENTATION…(3*)|(4)| The present research was funded in part by a grant from Physician's Exclusive LLC to the University of North Texas. The authors were not directly compensated for the completion of this work. Mo1907. . . . . EVALUATION OF METHODS FORTHE PRESERVATION…(2*) Mo1908. . . . . PROBIOTIC SEPSIS IN PATIENTSWITH INFLAMMATORY…(5*) Mo1909. . . . . DIRECT NUCLEIC ACID DETECTIONOF DIARRHEAL…(2*) Mo1910. . . . . COMMON BACTERIAL AND VIRALINFECTION IN…(5*) Mo1911. . . . . BACTERIOME AND MYCOBIOME ANALYSISUNDERSCORE THE…(2*) Mo1912. . . . . PSYCHOLOGICAL STRESS INDUCES DIFFERENTPATTERNS OF…(5*) Mo1913. . . . . LACTOBACILLUS CASEI DG® INPATIENTS WITH…(3*)| SOFAR SPA Trezzano Rosa, ITALY Mo1914. . . . . PROBIOTICS' EFFECTS ON PERCEPTIONOF HEALTH…(3*) Mo1915. . . . . PERTURBATION OF GUT MICROBIOMELEADS TO…(6*) Mo1916. . . . . DOES GUT MICROBIOTA-INDUCED METABOLICIMPROVEMENT AFTER…(4*)|(7) Mo1917. . . . . CHANGES IN THE BODYMASS INDEX…(5*) Mo1918. . . . . GASTRIC MICROBIOTA OF THEANTRUM IS…(4*) Mo1919. . . . . THE HISTONE H3K4 DEMETHYLASEKDM5 MODULATE…(2*)
Mo1920. . . . . ANTIBIOTIC SUSCEPTIBILITY OF PROBIOTICSTRAINS. IS…(3*)| Biocodex Laboratory Mo1921. . . . . ULCERATIVE COLITIS-ASSOCIATED ESCHERICHIA COLICOLONIZE THE…(4*) Mo1922. . . . . GAMMA-GLUTAMYLTRANSPEPTIDASE EXPRESSION BY HELICOBACTERSAGUINI, A…(2*) Mo1923. . . . . RIFAXIMIN DECREASES VIRULENCE OFCROHNS DISEASE…(3*)| This study was supported by Alfa Wassermann (Bologna, Italy). Mo1924. . . . . EVALUATION OF MULTIPLEX PCRFOR DIAGNOSIS…(5*) Mo1925. . . . . THE EFFECT OF METHANEON CALCIUM…(5*) Mo1926. . . . . TOWARDS UNDERSTANDING THE MECHANISMSOF HOW…(4*) Mo1927. . . . . PLASMA GHRELIN AND LEPTININ PATIENTS…(4*) Mo1928. . . . . BITTER TASTE RECEPTOR T2R138IN MOUSE…(2*) Mo1929. . . . . DIETARY REGULATION OF ENTEROENDOCRINECELL FUNCTION…(2*) Mo1930. . . . . NATURE AND THE SITEOF IMPAIRMENT…(2*) Mo1931. . . . . GENDER DIFFERENCE IN ANOREXIAFOLLOWING STRESS…(3*)| |Tsumura & Co.) Mo1932. . . . . DYNAMIC HEPATOSCINTIGRAPHY IN THEEARLY DIAGNOSIS…(1*)|(2) Mo1933. . . . . DUODENAL LAYER MORPHOMETRY TOGUIDE DUODENAL…(3*)| Study sponsored by Fractyl Laboratories, Inc.
Mo1934. . . . . SINGLE CATHETER FOR DUODENALMUCOSAL RESURFACING…(3*)| This trial is sponsored by Fractyl Laboratories Inc. Mo1935. . . . . GLU CAG+ ON LIKEPEPTIDE-1 (GLP-1)…(4*) Mo1936. . . . . META-ANALYSIS ASSESSING THE EFFECTOF LAPAROSCOPIC…(4*) Mo1937. . . . . FOREGUT EXCLUSION IS IMPORTANTIN THE…(4*) Mo1938. . . . . A HMG-COA REDUCTASE INHIBITOR,ROSUVASTATIN, AS…(5*) Mo1939. . . . . IMPACT OF ADIPOSITY ANDGLUCOSE HOMOEOSTASIS…(2*)|(4) Mo1940. . . . . MYOKINES SECRETED FROM EXERCISINGSKELETAL MUSCLES…(4*) Mo1941. . . . . HIGH RESOLUTION MANOMETRY REPRESENTSTHE HIGH…(5*) Mo1942. . . . . TYPE 2 DIABETES RESOLUTIONFOLLOWING ROUX-EN-Y…(4*) Mo1943. . . . . PROTECTIVE ROLE OF FLAVONOIDSAGAINST COLONIC…(4*) Mo1944. . . . . ROLE OF GUT-ADIPOSE-MUSCLE AXISIN BENEFICIAL…(5*) Mo1945. . . . . SHORT-TERM FOOD INTAKE, INTESTINALTRANSIT AND…(4*) Mo1946. . . . . PREDICTORS AND CORRELATES OFPRONENESS TO…(2*)|(4) Mo1947. . . . . THE IMPACT OF INDIVIDUALCOMPONENTS OF…(5*) Mo1948. . . . . BODY-MASS INDEX AND COLORECTALNEOPLASIA ACCORDING…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1949. . . . . ASSOCIATIONS AMONG ADIPOSITY, MEDIATINGBIOMARKERS AND…(5*) Mo1950. . . . . RISK OF SUICIDE ANDSELF-HARM IS…(5*) Mo1951. . . . . PSYCHIATRIC DISEASE DOES NOTNEGATIVELY IMPACT…(4*) Mo1952. . . . . ASSOCIATIONS OF OBESITY-RELATED NON-ALCOHOLICFATTY LIVER…(4*) Mo1953. . . . . SUCCESSFUL WEIGHT LOSS WITHLOW CARBOHYDRATE…(5*) Mo1954. . . . . FREQUENCY OF FUNCTIONAL GASTROINTESTINALDISORDERS IN…(5*) Mo1955. . . . . A COST-UTILITY ANALYSIS COMPARINGENDOSCOPIC, SURGICAL…(5*) Mo1956. . . . . THE IMPACT OF OBESITYON THE…(4*) Mo1957. . . . . ELEVATED SERUM TRANSFERRIN-IRON SATURATIONAND FERRITIN…(5*) Mo2042. . . . . LONG-TERM USE OF PROTONPUMP INHIBITORS…(5*) Mo2043. . . . . PROTECTIVE EFFECTS OF ALDA-1,AN ALDH2…(4*) Mo2044. . . . . VITAMIN D AND LOSARTANSUPPRESS COLONIC…(2*)|(4) Mo2045. . . . . IS CARDIORESPIRATORY FITNESS (VO2MAX)ASSOCIATED WITH…(4*)|(6) Mo2046. . . . . EICOSAPENTAENOIC ACID-FREE FATTY REDUCESFECAL CALPROTECTIN…(6*) Mo2047. . . . . HELICOBACTER PYLORI ERADICATION ASSOCIATEDWITH REDUCED…(2*)
Mo2064. . . . . PREDICTORS OF ADVANCED NEOPLASIAIN AVERAGE-RISK…(5*) Mo2065. . . . . PHASE II RANDOMIZED, DOUBLE-BLINDED,PLACEBO-CONTROLLED TRIAL…(2*)| NIH Grant 5R01CA132991 Mo2066. . . . . QUANTIFYING AREAS OF CONCERNON VOLUMETRIC…(5*) Mo2067. . . . . SPECTRAL PATTERN OF PANCREATICCANCER AND…(2*) Mo2068. . . . . COMPUTER-ASSISTED ANALYSIS OF HYPO-SCATTERINGGLANDULAR STRUCTURES…(2*) Mo2069. . . . . THE AVAILABILITY OF LINKEDCOLOR IMAGING,…(5*) Mo2070. . . . . INITIAL EXPERIENCE OF ELECTRONICCHROMOENDOSCOPY FOR…(5*) Mo2071. . . . . ABSENCE OF CONCERNING FINDINGSON VOLUMETRIC…(3*)| |NinePoint Medical, Inc.) Mo2072. . . . . ASSOCIATION BETWEEN CROSS-SECTIONAL ANDEN FACE…(2*) Mo2073. . . . . X-LINKED INHIBITOR OF APOPTOSISPROTEIN (XIAP)…(4*) Mo2074. . . . . DISTINCTIVE DNA MISMATCH REPAIRAND APC…(2*) Mo2075. . . . . MORPHOLOGIC AND MOLECULAR FEATURESOF SESSILE…(5*) Mo2076. . . . . DISCOVERY AND DERIVATION OFSPECIFIC BIOSIGNATURES…(2*) Mo2077. . . . . NUDT15 R139C-RELATED THIOPURINE LEUKOCYTOPENIAIS MEDIATED…(5*) Tu1050. . . . . DECISION AID FOR SHAREDDECISION MAKING…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1051. . . . . IMPACT OF AFFORDABLE CAREACT ON…(4*) Tu1052. . . . . FEASIBILITY OF MOBILE CBTFOR GENERALIZED…(3*)|(4)| Thrive Network, Inc (DBA, Lantern), the company which created and owns the mobile application, provided the virtual CBT app at no cost to the 12 participants of the study. Tu1053. . . . . SAFETY AND EFFICACY OFNON-ANESTHESIOLOGIST ADMINISTRATION…(5*) Tu1054. . . . . THE INCORPORATION OF MEDICALSCRIBES INTO…(1*) Tu1055. . . . . EFFECTIVENESS OF TELEPHONE REMINDERSVS. SHORT…(4*) Tu1056. . . . . ACADEMIC GASTROENTEROLOGY: THE TOPONE PERCENT…(5*) Tu1057. . . . . REGIONAL PRACTICE VARIABILITY OFREPEAT ESOPHAGOGASTRODUODENOSCOPY… (2*)|(4) Tu1058. . . . . THE IMPACT OF TRAVELDISTANCE ON…(5*) Tu1059. . . . . A CAUSE FOR HEARTBURN:A CLOSER…(5*) Tu1060. . . . . THE EFFECT OF ACETAMINOPHEN(PARACETAMOL) LEGISLATION…(5*) Tu1061. . . . . TELEMEDICINE: A MODERN APPLICATIONIN THE…(5*) Tu1062. . . . . PRACTICE PATTERNS OF CHOLECYSTECTOMYFOLLOWING ERCP…(4*) Tu1063. . . . . DESPITE HIGH INTEREST INTELEMEDICINE VIDEO…(2*) Tu1064. . . . . BURDEN AND YIELD OFREPEAT HELICOBACTER…(5*)
Tu1065. . . . . DEVELOPMENT OF A COLORECTALCANCER SCREENING…(5*) Tu1066. . . . . PEDIATRIC ACCESS TO FECALMICROBIOTA TRANSPLANTATION…(6*)|(5) Tu1067. . . . . TEMPORAL TRENDS IN PRE-DIAGNOSISSCREENING AND…(5*) Tu1068. . . . . OUTCOMES OF HCV MANAGEMENTBY MID-LEVEL…(5*) Tu1069. . . . . ERADICATION RATES OF HELICOBACTERPYLORI WITH…(5*) Tu1070. . . . . PROSPECTIVE IMPLEMENTATION OF ALGORITHMICPATIENT SELECTION…(5*) Tu1071. . . . . PREDICTORS OF PATIENT RELUCTANCETO USE…(2*) Tu1072. . . . . INCONSISTENCY BETWEEN ELECTRONIC DATAOF PATIENT'S…(5*) Tu1073. . . . . ANALYSIS OF UNMET NEEDSOF INDIVIDUALS…(2*)|(6) Tu1074. . . . . CAN WE PREDICT ADHERENCETO TREATMENT…(5*) Tu1075. . . . . MANAGEMENT OF CONSTIPATION INSECONDARY CARE.…(5*) Tu1076. . . . . TRENDS IN SOCIAL MEDIAPRESENCE AND…(5*) Tu1077. . . . . SYMPTOM CHECKERS VS. DOCTORS,THE ULTIMATE…(5*) Tu1078. . . . . EFFECT OF ENHANCED RECOVERYPROGRAMMES ON…(5*) Tu1079. . . . . CURRENT MANAGEMENT OF OGILVIE'SSYNDROME …(5*) Tu1080. . . . . FILAGGRIN AND TIGHT JUNCTIONPROTEINS ARE…(5*)
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1264. . . . . FEW PATIENTS WITH YOUNG-ONSETCOLORECTAL CANCER…(5*) Tu1265. . . . . INCIDENCE AND SURVIVAL INGASTRIC ADENOCARCINOMA…(5*) Tu1266. . . . . SQUAMOUS CELL CARCINOMA OFTHE STOMACH…(5*) Tu1267. . . . . OUTCOMES OF PRIMARY SQUAMOUSCELL CARCINOMA…(5*) Tu1268. . . . . DISTINCT PATIENT AND TUMORCHARACTERISTICS OF…(4*)|(6) Tu1269. . . . . THE ASSOCIATION BETWEEN OBESITY,METABOLIC HEALTH,…(5*) Tu1270. . . . . AN EPIDEMIOLOGICAL ANALYSIS OFGASTRIC CANCER…(5*) Tu1271. . . . . ELIMINATING RACIAL DISPARITIES: ESOPHAGEALCANCER TREATMENT…(5*) Tu1272. . . . . THE COST OF OBESITYON CANCER…(4*) Tu1273. . . . . IMPACT OF RACIAL DISPARITIESON CLINICAL…(5*) Tu1274. . . . . OUTCOMES OF LINITIS PLASTICAOF THE…(5*) Tu1275. . . . . PSYCHIATRIC MORBIDITY AND ITSIMPACT ON…(2*) Tu1276. . . . . INVESTIGATION, PREVALENCE AND HISTOLOGYOF COLORECTAL…(5*) Tu1277. . . . . COMPARATIVE OUTCOMES OF ESOPHAGEALCANCER TREATMENT…(5*) Tu1278. . . . . THE EFFECT OF OBESITYON EARLY…(5*) Tu1279. . . . . ONE EXPLANATION FOR THEREPORTED INCREASE…(5*)
Tu1280. . . . . MELANOMA INVOLVING THE GASTROINTESTINAL(GI) TRACT:…(5*) Tu1281. . . . . WHERE FIT FALLS SHORT:WHY PATIENTS…(5*) Tu1282. . . . . EPIDEMIOLOGICAL TRENDS IN ESOPHAGEALCANCER IN…(5*) Tu1308. . . . . IN VITRO AND EX-VIVOQUANTITATIVE ASSESSMENT…(3*)| Bayer Vital GmbH, Germany Tu1309. . . . . BILE REFLUX INCREASED THEINCIDENCE OF…(5*) Tu1310. . . . . HUMAN ESOPHAGEAL MYOFIBROBLAST IL-6SECRETION REGULATES…(2*) Tu1311. . . . . MACROPHAGE-DERIVED INDIAN HEDGEHOG DRIVESEPITHELIAL PROLIFERATION…(2*) Tu1312. . . . . HYDROTALCITE PROTECTS HUMAN ESOPHAGEALKERATINOCYTE PROGENITOR…(2*) Tu1313. . . . . CASE SERIES OF ESOPHAGEALLICHEN PLANUS:…(5*) Tu1314. . . . . ISOLIQUIRITIGENIN, A FLAVONOID COMPONENTOF LICORICE,…(5*) Tu1315. . . . . THE PREVENTION OF UPPERGASTROINTESTINAL BLEEDING…(3*) Tu1316. . . . . BIOAVAILABILITY OF ASPIRIN INRATS COMPARING…(2*) Tu1317. . . . . HYPOXIA-INDUCED SECRETOME OF ADIPOSE-DERIVEDMESENCHYMAL STEM…(2*) Tu1318. . . . . ROLE OF RELOOK UPPERGASTROINTESTINAL ENDOSCOPY…(5*) Tu1319. . . . . ANASTOMOTIC STRICTURES FOLLOWING ESOPHAGECTOMYFOR CORROSIVE…(5*)
Tu1320. . . . . PROTON PUMP INHIBITORS (PPI)INDUCES INCREASE…(2*) Tu1321. . . . . A RARE CASE OFESOPHAGEAL ACTINOMYCOSIS…(5*) Tu1322. . . . . NO LIGHT AT THEEND OF…(5*) Tu1323. . . . . SEEING IS BELIEVING: ARARE CASE…(5*) Tu1324. . . . . HOW TO COUNTERACT PERFORATEDSTOMACH LESION…(2*) Tu1325. . . . . SENSORY NERVES RELEASING CALCITONINGENE RELATED…(5*) Tu1326. . . . . COUNTERACTION OF PERFORATED CAECUMLESION IN…(2*) Tu1327. . . . . FIRST REPORTED CASE OFPEMBROLIZUMAB-INDUCED IMMUNE…(5*) Tu1328. . . . . CAUSTIC INGESTION: DEVELOPMENT ANDVALIDATION OF…(5*) Tu1329. . . . . AN UNUSUAL CASE OFESOPHAGEAL FOREIGN…(5*) Tu1330. . . . . GASTRIC ISCHEMIA: A RARECAUSE OF…(5*) Tu1331. . . . . LYMPHOCYTIC ESOPHAGITIS: A CASESERIES PROFILING…(5*) Tu1347. . . . . PANCREATIC EPITHELIAL CELL, BUTNOT IMMUNE…(2*) Tu1348. . . . . NF-KB GENETIC ABLATION EXERTSBENEFICIAL, BUT…(2*) Tu1349. . . . . THE EXTRACELLULAR CA2+ PROVIDEDBY RINGER'S…(2*) Tu1350. . . . . PATHOGENIC ALTERATION IN ENDOPLASMICRETICULUM HOMEOSTASIS…(2*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1351. . . . . MUTANT HUMAN PRSS1 R122HEXPRESSION IN…(2*) Tu1352. . . . . NALTREXONE AS A DISEASEMODIFYING THERAPY…(2*) Tu1353. . . . . PATHOGENESIS OF CHRONIC PANCREATITISIS INDEPENDENT…(2*) Tu1354. . . . . SIMULTANEOUS ACTIVATION OF K-RASAND NRF2…(5*) Tu1355. . . . . ACTIVIN IN ACUTE PANCREATITIS:POTENTIAL RISK-STRATIFYING…(7*)|(2) Tu1356. . . . . SITE-1-PROTEASE MEDIATED UNFOLDED PROTEINRESPONSE PROTECTS…(5*) Tu1357. . . . . NOVEL SMALL MOLECULE PKDINHIBITORS SUPPRESS…(2*) Tu1358. . . . . LIPOTOXICITY MAY RESULT ININFLAMMATORY CELL…(5*) Tu1359. . . . . EFFECT OF OCTREOTIDE ONPANCREATIC FIBROSIS…(2*) Tu1360. . . . . EFFECTS OF UNSATURATED FREEFATTY ACIDS…(2*) Tu1361. . . . . EXTRACELLULAR ATP PROMOTES SYSTEMICINFLAMMATION DURING…(2*) Tu1362. . . . . TOTAL SERUM CHOLESTEROL ANDPANCREATIC CANCER:…(2*)| The work was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000003. Tu1363. . . . . DIETARY ISOFLAVONE INTAKE ANDTHE DEVELOPMENT…(5*) Tu1364. . . . . DO PAST COMPUTED TOMOGRAPHYIMAGES HELP…(5*) Tu1365. . . . . CLINICAL USEFULNESS OF SERIALPANCREATIC-JUICE ASPIRATION…(5*)
Tu1366. . . . . NON-ALCOHOLIC FATTY PANCREAS DISEASE(NAFPD) AS…(5*) Tu1367. . . . . NATURAL HISTORY AND SIGNIFICANTFACTOR FOR…(5*) Tu1368. . . . . VASOACTIVE INTESTINAL PEPTIDE-SECRETING TUMORS:24 YEAR…(5*) Tu1369. . . . . PREVALENCE AND OUTCOMES OFPANCREATIC CYSTIC…(5*) Tu1370. . . . . RESECTABLE PANCREATIC NEUROENDOCRINE NEOPLASMS:CLINICOPATHOLOGICAL CHARACTERISTICS…(5*) Tu1371. . . . . TUMOR PROTEIN D52 ISAN AUTOPHAGY…(2*) Tu1372. . . . . TYPE 2 DIABETES ANDPANCREATIC EXOCRINE…(3*)| |AstraZeneca R&D) Tu1373. . . . . LOSS OF E-CADHERIN EXPRESSIONPROMOTES LOCAL…(5*) Tu1374. . . . . PANCREATIC ACINAR CELLS WITHHUMAN PRSS1R122H…(2*) Tu1375. . . . . RAB7 LOCALIZES TO ZYMOGENGRANULE MEMBRANE…(5*) Tu1376. . . . . 12 GENE PANCREATITIS SUSCEPTIBILITYPANEL: CLINICAL…(3*)| Ariel Precision Medicine Tu1377. . . . . ESTABLISHMENT OF INDIVIDUALIZED TREATMENTFOR PANCREATIC…(2*)| Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014R1A1A1006272) Tu1378. . . . . SBP-101 PRODUCES ATROPHY OFTHE EXOCRINE…(3*)| Sun Biopharma Inc. Tu1379. . . . . BETAINE PROTECTS THE PANCREASFROM ALCOHOL-INDUCED…(5*)
Tu1380. . . . . CILIATED PROTOZOANS RESTORE DIGESTIONAND AN…(2*)|(3)| This work was don as collaboration project, funded by the German ministry for research and education (BMBF). The partner Cilian AG received only part of their expenses from BMBF funding the other part was payed from Cilian's own resources. Tu1381. . . . . IMPACT OF TREATMENTS ONDIABETIC CONTROL…(5*) Tu1382. . . . . PRESENCE OF THE P21-ACTIVATEDKINASE, PAK4,…(2*) Tu1384. . . . . HEREDITARY PANCREATITIS IN THEUNITED STATES:…(5*) Tu1536. . . . . DIAGNOSTIC ESCAPE VARIANTS OFHEPATITIS B…(4*) Tu1537. . . . . BIRTH COHORT HCV SCREENINGRATES REMAIN…(3*)| |Grant from Gilead IN-US-342-4105) Tu1538. . . . . DIAGNOSTIC UTILITY OF LIVERBIOPSY IN…(5*) Tu1539. . . . . DECREASED CIRCULATING KYNURENINE ISASSOCIATED WITH…(4*) Tu1540. . . . . A LOW INCIDENCE OFHEPATOCELLULAR CARCINOMA…(5*) Tu1541. . . . . EFFICACY AND SAFETY OFPARITAPREVIR/RITONAVIR, OMBITASVIR…(5*) Tu1542. . . . . PATIENT EDUCATION AND HEALTHCAREPROVIDER CME:A…(3*)| This quality improvement initiative was funded through an independent medical educational grant from Gilead Sciences Medical Affairs Tu1543. . . . . DIMINISHING ROLE OF LIVERBIOPSY FOR…(5*) Tu1544. . . . . PREDICTORS OF LIVER STIFFNESSREGRESSION AFTER…(5*) Tu1545. . . . . THE PROGNOSIS OF HCVPATIENTS WITH…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1546. . . . . SUSTAINED VIRAL RESPONSE INPATIENTS WITH…(5*) Tu1547. . . . . ARE THERE PRE-DETERMINANTS FORELEVATED LIVER…(5*) Tu1548. . . . . FECAL MICROBIOTA TRANSPLANT USINGA PRECISION…(2*)| Materials Provided by Openbiome Tu1549. . . . . ALBUMIN USE AND ACUTEKIDNEY INJURY…(3*)| Investigator Initiated Grant from Grifols Pharmaceuticals Tu1550. . . . . STATINS DECREASE THE PROGRESSIONOF FIBROSIS,…(5*) Tu1551. . . . . ENDOTHELIAL FUNCTION AS APREDICTOR OF…(4*) Tu1552. . . . . IMPROVED MORTALITY AND LENGTHOF STAY…(5*) Tu1553. . . . . POST EVL (ENDOSCOPIC VARICEALLIGATION) ULCER…(5*) Tu1554. . . . . PREVALENCE AND NEW STARTSOF PROTON…(5*) Tu1555. . . . . MUSCLE VOLUME LOSS ASA PREDICTOR…(5*) Tu1556. . . . . OUTCOMES OF PATIENTS WITHALCOHOLIC RELATED…(5*) Tu1557. . . . . VANCOMYCIN IN ACUTELY DECOMPENSATEDCIRRHOTIC CAUSED…(5*) Tu1558. . . . . PORTAL TRIAD CLAMPING INRATS, AND…(2*) Tu1588. . . . . ADVANCED GLYCATION END PRODUCTSIMPAIR CA2+…(5*) Tu1589. . . . . ADVANCED GLYCATION END PRODUCTSINTERFERE WITH…(5*) Tu1590. . . . . ADVANCED GLYCATION END PRODUCTSACCUMULATED WITH…(5*)
Tu1591. . . . . SELECTIVE INHIBITION OF PROSTASININ HUMAN…(2*)|(4) Tu1592. . . . . THE OBESTATIN/G PROTEIN-COUPLED RECEPTOR39 (GPR39)…(2*) Tu1593. . . . . SORTING NEXIN 27 (SNX27)AFFECTS THE…(2*) Tu1594. . . . . KSR1/2 REGULATES ERK ACTIVATIONAND NEUROTENSIN…(2*) Tu1595. . . . . ACUTE EXPOSURE TO VITAMINC ACTIVATES…(4*) Tu1596. . . . . THE GHRELIN SIGNAL ENHANCEMENTEFFECT OF…(3*)| Tsumura & Co. Tu1597. . . . . ZINC ACTS AS APOTENT INHIBITOR…(4*) Tu1598. . . . . PSYCHOLOGICAL SYMPTOMS PREDICT CHANGESIN GASTROINTESTINAL…(4*) Tu1599. . . . . IMPACT OF RIFAXIMIN ONHEALTH-RELATED QUALITY…(3*)| This study was funded by Salix Pharmaceuticals, Raleigh, NC, USA Tu1600. . . . . PATIENT RESPONDER ANALYSIS FORA TOTAL…(3*)| IM HealthScience Tu1601. . . . . IN PATIENTS WITH IRRITABLEBOWEL SYNDROME-MIXED…(3*)| IM HealthScience Tu1602. . . . . LINACLOTIDE ATTENUATES VISCERAL ORGANCROSSTALK: IMPORTANCE…(3*)| Ironwood Pharmaceuticals, Cambridge, MA, USA. Tu1603. . . . . LYSOZYME MRNA DOWN-REGULATION ISASSOCIATED WITH…(2*) Tu1604. . . . . CHARACTERIZATION OF ABDOMINAL PAINRESPONSE IN…(3*)| Salix Pharmaceuticals, Raleigh, NC, USA Tu1605. . . . . YOUTUBE AS A SOURCEOF INFORMATION…(5*)
Tu1606. . . . . FOOD RELATED QUALITY OFLIFE IN…(4*) Tu1607. . . . . ASSOCIATION BETWEEN PREVALENCE OFFODMAP INTOLERANCE…(5*) Tu1608. . . . . HIGH FODMAP FOOD INTHE EVERYDAY…(6*)| Anemgi onlus Tu1609. . . . . IBS PATIENTS' BELIEFS ONFOOD-RELATED SYMPTOMS…(6*)| Anemgi Onlus Tu1610. . . . . AUTOPROBIOTIC: TREATMENT AND PREVENTIONOF FUNCTIONAL…(5*) Tu1611. . . . . CHANGES OF MICROBIOTA INRAT MATERNAL…(5*) Tu1612. . . . . IRRITABLE BOWEL SYNDROME PATIENTEXPERIENCE IN…(3*)| Allergan Inc. provided the Gastrointestinal Society with an unrestricted grant to conduct this survey. The physicians were not paid. Tu1613. . . . . INVESTIGATION ON SLEEP QUALITYOF PATIENTS…(5*) Tu1614. . . . . THE EFFECT OF ZESPRITMGREEN KIWIFRUIT…(3*)| Funding for the study came from Zespri International Limited Tu1615. . . . . SERUM PROTEOMIC ANALYSIS OFPATIENTS WITH…(5*) Tu1616. . . . . CLINICAL RESPONSE TO THELOW FODMAP…(2*)|(4) Tu1617. . . . . PSYCHOLOGICAL TREATMENTS FOR IRRITABLEBOWEL SYNDROME…(5*) Tu1619. . . . . SUSTAINED RESPONSE AND PREDICTORSOF SUSTAINED…(3*)| |Funding source: Salix Pharmaceuticals, Raleigh, NC.) Tu1620. . . . . CHOLECYSTOKININ RESPONSIVENESS VARIES ACROSSTHE POPULATION…(2*)|(4)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1669. . . . . THE PREVALENCE, CLINICAL PROFILESAND QUALITY…(4*) Tu1670. . . . . DOES INTRAVENOUS IMMUNOGLOBULIN BENEFITPATIENTS WITH…(5*) Tu1671. . . . . NO DIFFERENCE BETWEEN FUNCTIONALDYSPEPSIA PATIENTS…(5*) Tu1672. . . . . POTENTIAL OF VAGUS NERVESTIMULATION FOR…(5*) Tu1673. . . . . ASSESSMENT OF DUODENO/JEJUNAL BASELINEIMPEDANCE AS…(4*) Tu1674. . . . . MULTI-CENTER, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND,NON-INFERIORITY, PHASE…(3*)| This study was funded by Korea United Pharm. Inc. Tu1675. . . . . PERCEPTION VERSUS REALITY: DOESMARIJUANA HELP…(5*) Tu1676. . . . . CLINICAL CHARACTERISTICS AND DAILYGASTROINTESTINAL SYMPTOMS…(2*) Tu1677. . . . . TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION SYNCHRONIZEDWITH INSPIRATION…(5*) Tu1678. . . . . PREVALENCE OF GASTRIC MOTILITYDISORDERS IN…(5*) Tu1679. . . . . CHRONIC OPIOID USE INPATIENTS WITH…(5*) Tu1680. . . . . AMELIORATIVE EFFECT OF TJ-116ON DELAYED…(3*)| Tsumura & Co. Tu1681. . . . . STRESS AND STRESS-RELATED PEPTIDEAMPLIFY THE…(4*)|(3)|Tsumura &Co Tu1682. . . . . DOES SEVERITY OF GASTROINTESTINALSYMPTOMS CORRELATE…(5*)
Tu1683. . . . . GLUTEN FREE DIET IMPROVESUPPER GI…(4*) Tu1684. . . . . PATHOPHYSIOLOGICAL MECHANISMS OF IMPAIREDGLUCOSE HOMEOSTASIS…(2*) Tu1685. . . . . IMPACT OF FUNCTIONAL DYSPEPSIAAND ITS…(3*)| Supported by the research grant from Astrazeneca K.K. Tu1686. . . . . RELATIONSHIP BETWEEN BMI ANDTEMPORAL TRENDS…(2*) Tu1687. . . . . DETECTION OF POST-ENDOSCOPY INFECTIONOUTBREAKS USING…(4*) Tu1688. . . . . US NATIONAL TREND ANALYSISOF CYCLIC…(5*) Tu1689. . . . . DIARRHEA AND CLOSTRIDUM DIFFICILEINFECTION IN…(2*)| There is no industry or commercial sources of funding. Tu1690. . . . . INCIDENCE AND PREDICTORS OFEARLY HOSPITAL…(5*) Tu1691. . . . . COLDER WEATHER AND FEWERSUNLIGHT HOURS…(5*) Tu1692. . . . . RISK FACTORS FOR COLORECTALCANCER SIGNIFICANTLY…(2*) Tu1693. . . . . ADHERENCE TO A HEALTHYLIFESTYLE REDUCES…(2*) Tu1694. . . . . CHANGING EPIDEMIOLOGY OF LOWERGASTROINTESTINAL HEMORRHAGE…(5*) Tu1695. . . . . OUTCOMES OF WEEKEND VERSUSWEEKDAY ADMISSION…(5*) Tu1696. . . . . EPIDEMIOLOGY OF CONCURRENT USEOF PROTON…(5*) Tu1697. . . . . ASSOCIATION BETWEEN LOWER AIRPRESSURE AND…(5*) Tu1699. . . . . OBESITY INCREASES THE RISKOF GASTROINTESTINAL…(2*)
Tu1700. . . . . DEPRESSIVE PSYCHOLOGICAL STATUS ISASSOCIATED WITH…(5*) Tu1701. . . . . FATIGUE IS NOT ASSOCIATEDWITH VITAMIN…(1*)|(3)| Research grant from Tillots Pharma Tu1702. . . . . THE INFLUENCE OF METEOROLOGICALFACTORS ON…(5*) Tu1703. . . . . ANALYSIS OF RISK FACTORSAND CLINICOPATHOLOGICAL…(5*) Tu1704. . . . . EMERGENCY DEPARTMENT VISITS FORACUTE GASTROINTESTINAL…(5*) Tu1705. . . . . SHARED AUTOIMMUNITY AND CHRONICINFLAMMATORY DISEASE…(5*) Tu1706. . . . . PREVALENCE AND IMPACT OFDIABETES IN…(4*) Tu1707. . . . . AUTOIMMUNE GASTRITIS IN JAPAN:A STUDY…(5*) Tu1708. . . . . THE NUMBER AND LOCATIONOF LESIONS…(5*) Tu1709. . . . . THE ASSOCIATION BETWEEN INFLAMMATORYBOWEL DISEASE…(5*) Tu1710. . . . . INCREASING FREQUENCY OF HOSPITALIZATIONSAMONG YOUNG…(5*) Tu1711. . . . . TRENDS IN INCIDENCE ANDSURVIVAL OF…(5*) Tu1712. . . . . TIME TREND IN THEPREVALENCE OF…(5*) Tu1713. . . . . OUTCOME OF FECAL MICROBIOTATRANSPLANTATION FOR…(4*) Tu1714. . . . . PROCEDURAL-RELATED AND PATIENT-RELATED FACTORSINFLUENCE CLOSTRIDIUM…(5*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1715. . . . . ASPIRIN, STATINS AND STOOLPH LEVELS…(5*) Tu1716. . . . . DONORS ARE UNIVERSAL INTHE FIGHT…(3*)| Rebiotix Inc., Roseville, MN Tu1717. . . . . INCIDENCE, ADMISSION RATES ANDECONOMIC BURDEN…(5*) Tu1718. . . . . INCIDENCE OF CLOSTRIDIUM DIFFICILEIN PATIENT… (5*) Tu1719. . . . . MAGNITUDE AND NATURE OFASSOCIATION BETWEEN…(5*) Tu1720. . . . . STANDARDIZED OPENBIOME PRODUCT ASA TREATMENT…(5*) Tu1721. . . . . LACK OF ASSOCIATION WITHPATIENT DEMOGRAPHICS…(3*)| Rebiotix Inc., Roseville, MN Tu1740. . . . . CAN WE SIMPLIFY THEPEDIATRIC ULCERATIVE.COLITIS…(2*) Tu1741. . . . . ASSOCIATION OF AUTISM SPECTRUMDISORDERS AND…(2*) Tu1742. . . . . HOME OR HOSPITAL-BASED ANALYSISOF STOOL…(3*)| This project was financially supported by BÜHLMANN Laboratories AG, producer of both the IBDoc® method and the fCAL® ELISA assay used in this study. BÜHLMANN did not have a role in the design, execution, analyses, and interpretation of the data, or in the.. Tu1743. . . . . IS MESALAMINE MONOTHERAPY EQUALLYEFFECTIVE IN…(2*) Tu1744. . . . . MEDICATIONS AND SERUM BIOMARKERSARE ASSOCIATED…(2*)|(6) Tu1745. . . . . GREATER CONTRIBUTION OF HLATO RISK…(2*)|(4) Tu1746. . . . . EVALUATION OF ADALIMUMAB EFFECTIVENESSIN ANTI-TUMOR…(3*)| AbbVie
Tu1883. . . . . NEONATAL COLONIZATION WITH LF82INCREASES SEVERITY…(2*) Tu1884. . . . . LOW INTESTINAL IGA PRODUCTIONIN CVID…(2*) Tu1885. . . . . A ROLE FOR INNATELYMPHOID CELLS…(4*)|(6) Tu1886. . . . . MYCOBACTERIUM AVIUM SSP. PARATUBERCULOSIS(MAP) CAN…(4*) Tu1887. . . . . MACROPHAGES FROM CROHN'S DISEASEPATIENTS SHOWED…(6*)|(4) Tu1888. . . . . HELICOBACTER PYLORI INFECTION ISASSOCIATED WITH…(5*) Tu1889. . . . . CIRCULATING E. COLI OMPCPEPTIDE-SPECIFIC T…(6*)|(4) Tu1890. . . . . HDAC3 CONTROLS THE INFLAMMATORYRESPONSE AND…(3*)|(4) Tu1891. . . . . HDAC MEDIATED REGULATION OFTHE ANTIMICROBIAL…(2*)|(4) Tu1892. . . . . STARCH CONSUMPTION IS ASSOCIATEDWITH SEROLOGIC…(4*)|(6) Tu1893. . . . . IMPACT OF MICROBIOTA ONINTESTINAL IMMUNE…(2*)|(4) Tu1894. . . . . THE ESCHERICHIA COLI SMALLREGULATORY RNA…(6*)|(2) Tu1895. . . . . ACTIVATION OF GUT-ASSOCIATED TERTIARYLYMPHOID TISSUE…(2*) Tu1896. . . . . THE ROLE OF THEMICROBIOME IN…(4*) Tu1897. . . . . HUMAN NOROVIRUS-SPECIFIC T CELLRESPONSES …(2*) Tu1898. . . . . STEROID THERAPY FOR INFLAMMATORYBOWEL DISEASES…(2*)|(4)
Tu1899. . . . . HYALURONAN CONTROLS ADIPOSE TISSUEDEFENSE AGAINST…(5*) Tu1900. . . . . CATHELICIDIN ANTIMICROBIAL PEPTIDE LINKSVITAMIN D…(2*) Tu1901. . . . . PROTEOLYTIC CLEAVAGE OF SURFACEPD-L1 IN…(2*) Tu1902. . . . . THE PROTEIN COMPOSITION OFTHE HUMAN…(2*) Tu1903. . . . . GP96 DEFICIENCY PARTIALLY AFFECTSTLR4 FUNCTIONALITY…(2*)|(4) Tu1904. . . . . CROSS-LINKING OF THE MUC2MUCIN BY…(2*) Tu1905. . . . . GRAM-POSITIVE BACTERIA ARE HELDAT A…(4*) Tu1906. . . . . THE EFFECT OF VITAMIND ON…(7*)| This study was supported by a grant in aid of research from the Dairy Farmers of Canada. Tu1907. . . . . DIRECT INHIBITION OF HMGB1BY NEUTRALIZING…(2*) Tu1908. . . . . CIRCULATING NON-CLASSICAL MONOCYTES AREREDUCED IN…(3*)| This work was funded by an unrestricted grant from Takeda. Tu1909. . . . . THE LACK OF SECRETEDIGA SPONTANEOUSLY…(5*) Tu1910. . . . . THE IMPACT OF DIETAND OBESITY…(2*) Tu1911. . . . . DOES FECAL MICROBIOTA TRANSPLANTATIONFROM AN…(4*) Tu1912. . . . . QUALITY OF BOWEL PREPARATIONDOES NOT…(4*) Tu1913. . . . . FECAL MICROBIOTA TRANSPLANTATION ISSAFE AND…(4*) Tu1914. . . . . SHOULD WE RECOMMEND ANTI-CLOSTRIDIUM DIFFICILE…(4*)
Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1915. . . . . THE NOVEL ROLE OFA SERPIN-PRODUCING…(2*)|(4)|Nestle Research Center Tu1916. . . . . FECAL MICROBIOTA TRANSPLANTATION DIFFERENTIALLYINFLUENCES THE…(6*) Tu1917. . . . . AMINOSALICYLIC ACID DOWN-REGULATES GROWTHAND VIRULENCE…(6*)|(5) Tu1918. . . . . DONOR STOOL PROCESSING TIME:THE EFFECT…(6*) Tu1919. . . . . DONOR BODY MASS INDEX(BMI) DOES…(2*)|(3) Tu1920. . . . . FAECAL MICROBIOTA TRANSPLANTATION FORINFLAMMATORY BOWEL…(5*) Tu1921. . . . . OBESE STOOL DONORS INFECAL MICROBIOTA…(5*) Tu1922. . . . . THE EFFECT OF LACTOBACILLUSREUTERI (DSM…(5*) Tu1923. . . . . THE ROLE OF FECALMICROBIOTA TRANSPLANTATION…(6*) Tu1924. . . . . DOES RIFAXIMIN PRIOR TOFECAL MICROBIOTA…(6*) Tu1925. . . . . FECAL MICROBIOTA TRANSPLANTATION ISSAFE AND…(6*) Tu1926. . . . . EFFECT OF THE HERBALPREPARATION, STW…(3*)| Steigerwald Arzneimittelwerk GmbH, Bayer Consumer Health, Darmstadt, Germany Tu1927. . . . . ICU PHYSICIAN PROBIOTIC UTILIZATIONRATES: WHEN…(5*) Tu1928. . . . . PEPTOSTREPTOCOCCUS ANAEROBIUS INDUCES INTRACELLULARCHOLESTEROL BIOSYNTHESIS…(4*) Tu1929. . . . . THE INFLUENCE OF WESTERNIZATIONON THE…(2*)|(4)